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Abstract 
 
 Obesity is an increasingly prevalent condition that increases risk factors for type-
2 diabetes and heart disease. Weight loss reverses the complications of obesity. Long-
term maintenance of weight loss, however, is difficult. Mechanisms that improve 
metabolic health in obese people are therefore attractive targets for study. In my 
dissertation work, I have identified a novel role for Cholesteryl Ester Transfer Protein 
(CETP) to protect female mice against insulin resistance and exercise intolerance 
caused by obesity.  CETP is a lipid transfer protein that shuttles lipids between 
lipoproteins, culminating in delivery of cholesterol esters to the liver for secretion as bile. 
Bile acids are known to have insulin-sensitizing effects. Mice naturally lack CETP 
expression. I discovered that female mice transgenic for CETP were protected from 
high fat diet-induced insulin resistance. This effect was modest in males. In female mice 
I found activation of bile acid signaling pathways in liver and muscle as well as 
increased glucose rate of disappearance and increased muscle glycolysis. These 
results suggest that CETP can ameliorate insulin resistance associated with obesity in 
female mice by promoting muscle glucose utilization. 
 Based on the observations of improved muscle function in the CETP mice, I 
hypothesized that CETP could improve exercise capacity by increasing muscle 
oxidative metabolism. While there is no difference in exercise capacity between lean, 
chow fed CETP-expressing mice and their non-transgenic littermates, CETP-expressing 
female mice are protected against the decline in exercise capacity caused by obesity. 
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This improvement in exercise capacity corresponded with increased mitochondrial 
oxidative capacity. 
 My dissertation work has demonstrated a novel role for CETP to promote 
metabolic health in obese animals potentially through its effect on bile acid signaling to 
muscle. I propose that targeting bile acid signaling pathways could promote metabolic 
health in obese people. The sexual dimorphism observed adds to the growing body of 
evidence that CETP likely has a positive impact on metabolism in females. Further 
understanding the role of CETP and bile acid signaling will help to provide new 
strategies for promoting metabolic health in obese people. 
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CHAPTER I 
 
BACKGROUND AND SIGNIFICANCE 
 
Overview 
Obesity leads to insulin resistance, diabetes, and heart disease. Weight loss 
resolves the morbidities of obesity. Most people who lose weight, however, have great 
difficulty maintaining their level of weight loss [1, 2]. Additionally, obesity causes a 
reduction in exercise capacity, making weight loss through exercise more difficult and 
creating a vicious cycle of increasing weight and insulin resistance [3, 4]. Understanding 
factors that improve metabolic health in obese individuals could lead to improved 
treatment of obesity. Additionally, mechanisms that improve exercise capacity with 
obesity could help obese people to lose weight through exercise. Overall, my 
dissertation work has demonstrated that Cholesteryl Ester Transfer Protein (CETP) 
protects against the negative effects of obesity on insulin sensitivity and exercise 
capacity. 
CETP is a lipid transfer protein that facilitates the transfer of lipids between 
lipoproteins. Specifically, it allows for the exchange of Cholesteryl Esters (CE) and 
triglycerides (TG) between serum High Density Lipoprotein (HDL) and either Low 
Density Lipoprotein (LDL) or Very Low Density Lipoprotein (VLDL) [5]. CETP-mediated 
flux of TG to HDL destabilizes the scaffold of the HDL Apolipoprotein A1 (ApoA1) 
particle, resulting in decreased HDL cholesterol [6]. Animals that naturally lack CETP, 
such as mice, carry a much higher percentage of their total cholesterol in HDL. Since 
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CETP activity leads to reduced HDL, current models of HDL function suggest that CETP 
would increase risk of cardiovascular disease. Therefore, CETP inhibitor drugs were 
developed to increase HDL cholesterol and thereby protect against heart disease [7]. 
While CETP inhibitors potently increase HDL in humans, none to date has 
demonstrated clinical efficacy in reducing the incidence of heart attack [8, 9]. This lack 
of clinical efficacy despite robust increases in HDL suggests that CETP does not have a 
simple direct relationship with risk of cardiovascular disease and invites further study to 
better understand the specific role of CETP in metabolism.  
In contrast to its perceived negative effect on cardiovascular risk, CETP has a 
beneficial role in promoting reverse cholesterol transport, the removal of cholesterol 
from peripheral tissues and its delivery to the liver for secretion as bile. CETP 
expression improves hepatic uptake of cholesterol in a mouse model that is otherwise 
unable to clear HDL due to deficiency of Scavenger Receptor B1 (SR-B1) [10, 11].  In 
women, higher serum CETP activity correlated with increased radiolabeled cholesterol 
uptake from macrophages to serum in an ex vivo study. This effect was not observed in 
men [12]. Additionally, clinical studies have suggested that CETP has a beneficial effect 
on glucose homeostasis, especially in females. For example, a study of obese women 
who had undergone gastric bypass surgery showed that higher CETP mass correlated 
with improved glycemia 12 months post-op, an effect not observed in males [13]. 
Overall, studies in both mice and humans have shown that CETP can promote reverse 
cholesterol transport and potentially improve insulin sensitivity. These studies also 
suggest an important sexual dimorphism in the metabolic effects of CETP. 
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The increase in reverse cholesterol transport mediated by CETP likely leads to 
increased gut bile acids [11]. In the liver, CE are converted into bile acids and secreted 
into the gut. Beyond their role in digestion, bile acids activate three major signaling 
pathways that improve glucose metabolism: 1) Fibroblast Growth Factor 15 (Fgf15) 
signaling to the liver, 2) Farnesoid X Receptor (Fxr) signaling in the liver and gut, and 3) 
g-protein coupled bile acid receptor (Gpbar1 also known as Tgr5) signaling in muscle 
[14, 15]. Gpbar1 upregulates type-2 thyroid deiodinase (Dio2), causing increased 
energy expenditure and glucose oxidation by mitochondria [16-18]. Since Gpbar1 is 
associated with increased muscle glucose disposal, I hypothesize that bile acid 
signaling induced by CETP activity leads to improved insulin sensitivity  
I propose that CETP also has a role in increasing exercise capacity, which is 
known to decline with obesity [4]. Mechanisms that help improve exercise capacity 
could help to improve metabolic health and quality of life for obese people. Exercise 
capacity relies heavily on glucose oxidative capacity as a fuel source for muscle, 
especially at higher levels of exercise intensity [19]. Since I discovered that CETP 
expression alters pathways that lead to improved glucose oxidative capacity, I 
hypothesized that CETP expression might increase exercise capacity by allowing for 
increased muscle glucose oxidation. 
Overall, recent studies of CETP suggest that it may have a beneficial role in 
metabolic health. My dissertation project demonstrates that CETP expression improves 
both insulin sensitivity and exercise capacity in obese female mice. Thus, CETP 
expression improves major complications of obesity such as insulin resistance and 
impaired exercise capacity. 
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Obesity significantly increases risk of chronic metabolic disease 
           Obesity, defined as the accumulation of excess body fat, is the greatest public 
health challenge of the 21st century. It is linked to the metabolic syndrome, a condition 
characterized by increased fasting blood glucose, reduced HDL cholesterol, increased 
serum triglycerides, and hypertension. These factors combine to create an increased 
risk of cardiovascular disease [20]. Body mass index (BMI), defined as an individual’s 
weight in kilograms divided by the square of their height in meters, provides a metric 
definition of obesity. An individual is classified as obese with a BMI of over 30 and 
overweight with a BMI of 25-30. Increasing BMI correlates with increased risk of 
developing diabetes and cardiovascular disease. Compared to people with a BMI of 25 
and adjusted for age, a man with a BMI of over 35 has a 42-fold greater relative risk of 
diabetes [21], and a woman with a BMI of over 35 has a staggering 93-fold greater 
relative risk of diabetes [22]. This large increase in relative risk of diabetes reflects not 
only the low prevalence of diabetes in lean individuals but also illustrates that obesity 
dramatically increases the risk of diabetes. Similarly, obesity increases the risk of 
coronary heart disease (CHD) by 2.0-fold in men and 2.4-fold in women [23]. 
Understanding risk factors that contribute to the development of metabolic disease with 
obesity will improve outcomes for patients who are affected by the increasingly 
prevalent condition of obesity. 
Obesity is a quickly increasing problem throughout the world. Once thought to be 
a problem limited to the developed world, obesity has increased worldwide to the point 
that it was declared a global epidemic in 1997 [24]. In 2011, the World Health 
Organization estimated that approximately 500 million people worldwide, or nearly 10% 
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of the world population, were obese [25]. As of 2012, 35% of the population of the 
United States, over 100 million people, was reported as obese [26]. Since obese people 
make up a large portion of the patient population, the costs of treating the metabolic 
complications of obesity have been estimated to be 20.6% of the total healthcare 
expenditure in the Unites States, representing a significant financial burden [27]. Yearly 
spending on health care for obesity-related complications in the United States is 
estimated to increase by as much as 66 billion dollars by 2030 [28].  Preventing the 
metabolic complications of obesity could therefore help to alleviate the great financial 
burden that obesity presents to governments and health care systems as well as 
improve quality of life for people with obesity. 
Weight loss reverses the deleterious effects of obesity. For example, a study in 
obese patients who reduced caloric intake and increased physical activity showed that 
for every kg of weight lost the risk of diabetes dropped by 16% [28]. Weight loss of 
between 5% and 10% of body weight correlates with improvements in glycemia, serum 
HDL and triglyceride levels, and blood pressure [29]. Maintaining weight loss over time, 
however, is difficult; people often regain weight and reach their former body weight. A 
2005 study showed that only 20% of people who lost more than 10% of their body 
weight maintained this level of weight loss for at least one year [2]. Individuals who 
successfully maintained weight loss were more likely to adhere to diet and exercise 
plans and were less likely to suffer from depression than those who regained weight. 
Since the rate of successful maintenance of weight loss is so low, factors that improve 
metabolic health in the context of obesity are attractive targets for study. 
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A known factor that improves metabolic health in the context of obesity is female 
sex. Estrogen, a major female sex hormone, has been proposed to promote insulin 
sensitivity. Premenopausal women, who have high levels of estrogen compared to 
postmenopausal women or men, show improved glucose tolerance, reduced risk of 
developing insulin resistance, and higher levels of Glut4 in adipose tissue [30, 31]. 
Estrogen signaling is important to insulin sensitivity even in men, as men with 
aromatase deficiency that completely lack estrogen are insulin resistant [32]. After 
menopause, when estrogen levels drop, women are prone to develop increased body 
weight, hyperinsulinemia, and insulin resistance [33, 34]. Estrogen signals through two 
major receptors, Estrogen receptor alpha (ERα) and Estrogen receptor beta (ERβ). The 
major form of estrogen receptor in the liver is ERα [35]. Estrogen receptors are nuclear 
receptors that dimerize in response to ligand binding. Once activated, they bind to 
estrogen response elements (ERE) in the promoter of target genes to activate 
transcription. Knockout of estrogen receptor alpha in mice results in impaired glucose 
tolerance and insulin resistance [36]. Overall, female sex and specifically estrogen 
signaling are factors that promote healthy glucose metabolism.  
Additionally, women are protected against the effects of obesity on increased risk 
of CHD, a condition caused by blockages of blood vessels that supply blood to the heart 
that can manifest as an acute event known as a myocardial infarction (MI), also known 
as a heart attack.  One of the major complications of obesity is increased risk of CHD 
[22, 23, 37].  CHD is a subset of cardiovascular disease, which includes a number of 
different disorders of the heart and blood vessels including coronary heart disease, 
cerebrovascular disease, peripheral artery disease, congenital heart disease, deep vein 
7	  
	  
thrombosis, and pulmonary embolism. Women have a lower risk of heart attack 
compared to men of a similar age, with risk of death from MI in women being that of a 
man ten years younger [38]. Women are also relatively protected against the increase in 
CHD risk with weight gain, as increasing body weight correlates with a much larger 
increase in CHD incidence in men compared to women [23]. CHD, however, remains a 
major cause of death in women, and incidence of CHD increases sharply in 
postmenopausal women [39]. Since CHD is a major cause of death, medical science 
has focused on understanding and treating this disease 
        Cardiovascular risk factors were defined in a seminal research study performed 
between the 1940s and 1960s called the Framingham Heart Study. The study followed 
a population of 5400 individuals from the town of Framingham, Massachusetts and 
identified risk factors for the development of cardiovascular disease. Over the course of 
the Framingham Heart study, the following classical risk factors for cardiovascular 
disease were identified: 1) hypertension [40], 2) increased LDL cholesterol [41], 3) 
decreased HDL cholesterol [41], 4) male sex [42], and 5) smoking [40].  
 Based on these findings, clinical guidelines were developed that have helped to 
improve the treatment and prevention of cardiovascular disease. These improvements 
in treatment have been largely effective, and the rates of cardiovascular disease within 
the United States have declined sharply since the 1970s. In the 1970s nearly 1,000,000 
people died each year from cardiovascular disease. By 2007 the number of deaths from 
cardiovascular disease had been reduced by 20% to 800,000 [43]. Our understanding 
of cardiovascular risk factors, however, is still largely based on the Framingham study, 
which was performed in a patient population that was mainly lean. By contrast, in the 
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2010s, the general population is approximately 30% obese and nearly 50% overweight. 
Obesity presents a challenge to the treatment of CHD, as it causes insulin resistance 
and diabetes, which are linked to increased risk of cardiovascular disease [22, 23, 37].  
 
Insulin signaling 
Insulin signaling is crucial to regulation of metabolic processes in tissues 
throughout the body. Insulin is a 51-amino acid (5.8 kd) peptide hormone that is 
produced in pancreatic beta cells and secreted into the serum in response to elevated 
blood glucose. Insulin signals to the liver to reduce glucose production, promote storage 
of nutrients as glycogen and fatty acid, and inhibit the release of triglyceride from the 
liver in the form of VLDL [44-49]. Insulin also promotes the uptake of glucose by muscle 
and adipose tissue [50, 51]. Insulin achieves these effects by activating a complex 
signaling network that has three major nodes: the insulin receptor, phosphoinositide 3-
kinase (PI3K), and protein kinase b (AKT). The insulin signal is initiated when insulin 
binds to the insulin receptor, which is a transmembrane protein with tyrosine kinase 
activity. Activation of the insulin receptor causes tyrosine autophosphorylation of the 
insulin receptor [52]. Phosphorylation of the insulin receptor leads to tyrosine 
phosphorylation of insulin receptor substrates (IRS) by the insulin receptor [53]. 
Phosphorylated IRS, in turn, phosphorylates PI3K, which catalyzes the production of the 
lipid second messenger phosphatidylinositol trisphosphate (PIP3) from 
phosphatidylinositol bisphosphate (PIP2). PIP3 binds AKT to the cellular membrane and 
allows for AKT phosphorylation at threonine 308 by Phosphoinositide-dependent 
kinase-1 and at serine 473 by mTORc2 [54-58].  
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AKT serves as a signaling nexus that is a master regulator of metabolic 
processes. AKT downregulates gluconeogenesis by deactivating the transcription factor 
Forkhead Box Protein O1 (FoxO1), which transcriptionally upregulates genes whose 
products control gluconeogenesis, including phosphoenylpyruvate carboxykinase (Pck), 
and glucose-6 phosphatase (G6pc) [59]. FoxO1 also transcriptionally upregulates 
microsomal triglyceride transfer protein (Mttp), which functions to promote the lipidation 
of VLDL and has the net effect of increasing TG release from the liver [60]. Therefore, 
insulin signaling to AKT suppresses release of TG from the liver in the form of VLDL. In 
addition to its regulation of FoxO1, AKT activates glycogen synthesis by 
phosphorylating glycogen synthase kinase 3 (Gsk3), leading to activation of glycogen 
synthase [61]. In addition, AKT can activate mTOR to promote protein synthesis and 
muscle hypertrophy[62]. Both AKT and IRS signaling can activate the growth factor 
signal ERK1/2, AKT through activation of Raf and IRS through activation of Ras [63-65]. 
 Insulin signaling also activates de-novo lipogenesis in the liver through activation 
of the transcription factor sterol regulatory element binding partner 1c (SREBP-1c), 
which transcriptionally upregulates genes whose products control fatty acid synthesis 
such as fatty acid synthase (Fas) and acetyl coA carboxylase (Acc). Insulin signaling 
both increases the transcription of SREBP-1c and promotes its cleavage to its mature, 
transcriptionally active form [66, 67].  
Insulin signaling has an important role in muscle and adipose tissue to promote 
glucose uptake by these tissues. Insulin treatment of these tissues results in increased 
glucose uptake through translocation of glucose transporter 4 (Glut4) from intracellular 
vesicles to the plasma membrane [68, 69]. Insulin signaling to AKT is crucial to the 
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membrane translocation of Glut4, as constitutively active AKT causes increased Glut4 
translocation and glucose uptake [70], and dominant negative AKT impairs the ability of 
insulin to promote Glut4 translocation [71, 72]. AKT phosphorylates AS160 at multiple 
sites, and mutation of these phosphorylation sites blunts the ability of insulin signaling to 
promote Glut4 translocation [73].  AS160 has rabGTPase activity that suppresses Rab 
proteins that are required for translocation of Glut4 [73]. AKT signaling inhibits the 
GTPase activity allowing for activation of Glut4 translocation [74]. Uptake of glucose by 
muscle and adipose tissue is crucial for storage of energy as glycogen in muscle and 
fatty acid in adipose tissue.  
 
Insulin resistance 
Unfortunately, cells and tissues can fail to properly respond to an insulin signal, a 
condition known as insulin resistance.	  Insulin resistance is marked by the failure of 
tissues such as liver and muscle to properly respond to an insulin signal, resulting in 
impaired glucose tolerance, increased blood glucose, and increased serum triglycerides 
[75]. The progression from insulin resistance to type-2 diabetes occurs as the pancreas 
secretes increasing levels of insulin in an attempt to compensate for the insulin 
resistance [76, 77]. Eventually the pancreas cannot produce enough insulin to keep 
pace with the level of insulin resistance, and the pancreatic beta cells can fail to 
continue producing sufficient insulin, resulting in type-2 diabetes [78].  Insulin resistance 
is associated with obesity and physical inactivity [79, 80]. 
 At the molecular level, insulin resistance is associated with accumulation of 
excess lipid in liver and muscle, particularly diacylglycerols and fatty acyl coAs. In 
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muscle, diacylglycerols activate PKCβ, which causes serine phosphorylation of IRS1, 
interfering with normal insulin signaling to promote glucose uptake and glycogen 
storage [81, 82]. In the liver, a similar process occurs. Diacylglycerols activate PKCε, 
which causes serine phosphorylation of the insulin receptor, disrupting its ability to 
phosphorylate IRS, leading to reduced glycogen synthesis and increased 
gluconeogenesis, as the downstream signals to AKT and GSK3 are disrupted [83]. 
These changes in signaling have the net effect of altering whole-body metabolism. 
At the systemic level, insulin resistance results in reduced muscle glucose uptake, 
failure to suppress hepatic glucose production, and increased plasma free fatty acids 
(FFA) [75, 84, 85]. Moderate levels of insulin resistance cause a compensatory increase 
in insulin secretion from the pancreas, and an individual with modest insulin resistance 
may have normal blood glucose but chronically elevated insulin and expansion of beta 
cells in the pancreas [86]. Over time, increasing levels of plasma glucose interfere with 
the normal process of glucose stimulated insulin resistance, as it is hypothesized that 
beta cells are attuned to specific levels of glucose above which they do not function 
properly [86]. Further progression of insulin resistance causes decompensation, the 
process by which beta cells fail to keep pace with the insulin demand produced by the 
levels of circulating glucose. This decompensation is thought to be caused by 
glucotoxicity interfering with the ability of beta cells to produce normal levels of insulin 
[87, 88]. The progression to insulin-dependent diabetes is caused by deficiency of beta 
cells. The reduction in beta cells is caused either by increased beta cell apoptosis or 
reduced beta cell proliferation; however, studies in humans have suggested that 
increased apoptosis is a greater factor than impaired proliferation [89, 90].  
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A proposed mechanism that could promote insulin secretion even in the context 
of type-2 diabetes is glucagon-like peptide 1 (Glp1). Glp1 is an incretin hormone 
released from the gut in response to a mixed meal [91]. Glp1 promotes glucose-
stimulated insulin secretion, and its effects on insulin secretion are seen even in 
individuals with type-2 diabetes [92, 93].  Additionally, Glp1 has been implicated in beta 
cell proliferation, as it has been shown to increase beta cell proliferation in mice and 
upregulate the transcription factor pancreatic duodenal homeobox 1 (Pdx1), which 
signals to promote beta cell survival and maturation [94, 95]. In a rodent model of 
diabetes, Glp1 administration resulted in increased insulin secretion, decreased 
glycemia, and increased beta cell mass [96]. Since Glp1 is secreted from the gut, it 
suggests an interplay between gut signaling and insulin secretion and sensitivity.  
Patients with diabetes have an increased risk of cardiovascular disease. While 
the treatment of cardiovascular disease has improved, diabetes still correlates with a 
two to three fold increased risk of death from cardiovascular disease. In a study of the 
Framingham and Framingham Offspring cohorts, rate of death from cardiovascular 
disease decreased from 12.8 to 7.7 deaths per 1000 person-years between 1975 and 
2001 in people without diabetes. In patients with diabetes, the rate of death dropped 
from 33.1 to 15.8. While this reflects a significant reduction in both groups, having 
diabetes still correlates with the same two to three fold higher risk of death from 
cardiovascular disease in 2001 as it did in 1975 [97]. The fact that diabetes still 
increases risk of CHD despite improved treatment suggests that additional risk factors 
in people with diabetes have not been targeted. Understanding these risk factors will 
help to decrease incidence of CHD in people with diabetes. 
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Lipoprotein biochemistry and function 
Obesity and insulin resistance contribute to dysregulation and dysfunction of 
lipoproteins, which contributes to increased risk of CHD. Lipoproteins are critical to 
transport of lipids throughout the circulation, as lipids are not soluble in the aqueous 
blood. Three major classes of lipoproteins, VLDL, LDL, and HDL, contribute to the 
circulation of lipids, primarily cholesterol and triglycerides, between cells and tissues.  
Both Low Density Lipoprotein (LDL) and Very Low Density Lipoprotein (VLDL) 
are associated with the apolipoprotein ApoB100. Each VLDL or LDL particle includes 
one ApoB100 molecule [98]. ApoB100 is a very large protein containing 4536 amino 
acids (550 kd). ApoB100 is produced in the liver and begins to be lipidated in the rough 
ER while still being translated. If not lipidated, ApoB100 does not fold properly and is 
broken down by proteasomal degradation. Lipidation of ApoB100 occurs through the 
action of microsomal triglyceride transfer protein (MTP) to form a VLDL precursor [99, 
100]. Additional lipidation of the VLDL precursor results in the formation of a lipid-poor 
mature VLDL particle known as VLDL2 [101]. Further lipidation creates a triglyceride-rich 
VLDL particle known as VLDL1 [101]. In the serum, VLDL can be de-lipidated through 
the action of lipoprotein lipase (LPL), resulting in a smaller and less lipid-rich 
intermediate density lipoprotein (IDL) [102]. IDL can then be further de-lipidated through 
the action of hepatic lipase to form LDL, which contains mainly cholesterol [103]. 
Insulin regulates the production of VLDL, and insulin resistance significantly 
increases the levels of circulating TG contained in VLDL. Assembly of VLDL is 
regulated by MTP, which is transcriptionally upregulated by FoxO1 [60]. Since insulin 
signals to inactivate FoxO1, VLDL assembly is downregulated in response to an insulin 
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signal. Insulin resistance therefore causes increased activation of FoxO1, increased 
levels of MTP, and increased VLDL-TG in plasma [104].  Additionally, insulin resistance 
appears to be “pathway selective,” as in the insulin-resistant state insulin fails to 
suppress hepatic gluconeogenesis, but insulin still promotes de novo lipogenesis 
through SREBP-1c activation [105]. Therefore, in the insulin-resistant state there is both 
a higher level of lipid to load onto nascent VLDL and increased levels of MTP, which 
performs the lipidation of nascent VLDL. These factors combine to increase circulating 
VLDL triglyceride in insulin resistance. 
LDL is also an apoB100 containing lipoprotein and has just one molecule of 
ApoB100 per LDL particle. LDL particles are about half the size of the larger VLDL 
particles, with the average circulating human LDL particle being about 250 angstroms in 
diameter [106]. LDL is primarily a carrier of cholesterol, with over 60% of the LDL 
particle consisting of CE or FC [107]. The primary function of LDL is to provide 
cholesterol to cells and tissues, which is critical for normal membrane function. LDL is 
cleared from the circulation by the activity of LDL receptor (LDLR). LDLR binds to LDL 
and internalizes it through receptor-mediated endocytosis [108]. Once internalized, the 
protein structure of LDL is broken down to amino acids, and the cholesterol ester cargo 
is hydrolyzed to free cholesterol [109, 110].  Through this mechanism, LDL and its cargo 
are completely removed from the circulation. Normal function of LDL receptor is critical 
to clearance of LDL from the circulation, as both LDL receptor knockout mice and 
people with dysfunctional LDL receptor exhibit drastically increased levels of circulating 
LDL cholesterol [111, 112].  
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In population studies, LDL cholesterol has been associated with risk of CHD [41]. 
The modification of LDL contributes to its pro-atherogenic reputation. Triglyceride 
enrichment of LDL, which is caused by the hypertriglyceridemia associated with obesity 
and insulin resistance, contributes to formation of small, dense LDL particles, which are 
associated with increased risk of CHD [113]. Small dense LDL has reduced affinity for 
the LDL receptor and increased interaction with artery wall proteoglycans. This 
combination of factors increases the risk of LDL contributing to formation of 
atherosclerotic lesions that contribute to CHD.  
In contrast to LDL and VLDL, Apolipoprotein A-1 (ApoA-1) is central to the 
structure of HDL. ApoA-1 is a 243 amino acid protein (28 kd) that has 10 alpha helix 
domains [114, 115]. The c-terminal region of human apoA-1 is highly hydrophobic and 
is critical for lipid binding [114, 116]. Apo-A1 is produced in the liver and secreted into 
the circulation. As Apo-a1 binds lipids, a conformational shift occurs that allows for 
additional lipid binding [117]. As Apo-A1 collects lipids, a nascent HDL particle forms 
that has a discoidal shape. Two molecules of Apo-A1 wrap around the discoidal HDL 
particle in a “double-belt” conformation [118]. Mature HDL particles consist of a neutral 
lipid core mainly composed of CE and TG enveloped by a phospholipid monolayer. 
Spherical HDL is bounded by three ApoA1 particles that are arranged in a trefoil 
conformation [119]. The activity of lecithin—cholesterol acyltransferase (LCAT) is crucial 
to the formation of spherical HDL, as it converts free cholesterol (FC) to CE, which is 
poorly soluble in the phospholipid bilayer [120]. Mature HDL is cleared of cholesterol in 
the liver through the activity of SR-B1, which is crucial to HDL function. 
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HDL’s major function is to reverse cholesterol transport (RCT), the movement of 
cholesterol from peripheral cells to the liver for excretion from the body. The first step in 
RCT is the uptake of cholesterol from macrophages to nascent HDL involving the 
loading of FC onto lipid-free/poor apoA1 [121]. ATP binding cassette A1 (ABCA1) plays 
an important role in this process by actively transporting lipids from macrophages to 
nascent HDL. Deficiency of ABCA1 is associated with Tangier disease, a condition 
marked by extremely low levels of HDL and accumulation of cholesterol in peripheral 
tissues [122]. FC is esterified by LCAT in HDL, and the CEs are then transported to the 
liver. In the liver, HDL docks to SR-B1, which facilitates the flux of CE into the liver [123]. 
SR-B1 facilitates movement of CE along its concentration gradient into liver cells; 
therefore, more CE rich HDL will have a higher rate of CE transfer to the liver [124].  
Additionally, CE can be transferred from HDL to LDL, which can then be cleared by 
LDLR in the liver, contributing to the transport of cholesterol to the liver.  Overall, the 
process of reverse cholesterol transport is important to health, as excess cholesterol in 
macrophages contributes to atherosclerosis, a significant risk factor for CHD [125]. 
Obesity and insulin resistance contribute to dysfunction of HDL. Particularly, the 
hypertriglyceridemia associated with obesity and insulin resistance correlates with 
decreased levels of HDL [126]. The cause of this relationship is likely TG enrichment of 
HDL in the context of hypertriglyceridemia. Elevated levels of TG in VLDL result in 
increased transfer of TG to HDL through the activity of CETP [127]. TG enrichment of 
HDL makes it a better substrate for modification by hepatic lipase [128]. This 
modification results in increased uptake of Apo-A1 by the kidney, resulting in decreased 
HDL levels [129]. TG enrichment of HDL has also been associated with increased 
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clearance of HDL in humans [130]. Since population studies have shown that reduced 
levels of HDL correlate with increased risk of CHD, it would suggest that CETP activity 
contributes to CHD risk.  
 
Cholesteryl ester transfer protein 
 CETP is involved in both lipoprotein biology and whole-body glucose metabolism 
and has been studied as a factor that might alter the risk of CHD. CETP is a 78kd 
glycoprotein that is produced mainly in the liver and adipose tissue and secreted into 
the serum. In the serum, CETP has lipid transfer activity to shuttle TG and CE between 
HDL and LDL/VLDL, resulting in TG enrichment of HDL (Figure 1.1) [5]. In the context 
of obesity and elevated serum TG, CETP activity has the net effect of reducing HDL by 
transferring TG to HDL, destabilizing the ApoA1 scaffold of HDL and increasing its 
clearance [6]. Since reduced HDL is an established risk factor for CHD, inhibition of 
CETP became a drug target with the goal of increasing HDL and reducing CHD. Studies 
of genetic variants that correlate with varying degrees of CETP activity have shown 
conflicting results on the relationship between CETP activity and human health. 
Additionally, CETP inhibitor drugs have not proven effective at reducing the risk of 
CHD.  Recent research has shown that CETP has the ability to promote reverse 
cholesterol transport and increase bile acid secretion, which may contribute to improved 
glucose metabolism [10, 11]. Clinical studies of CETP have suggested a sexually 
dimorphic role for CETP, with CETP having a positive effect on reverse cholesterol 
transport and glucose metabolism in women [12, 13, 131]. Overall, I propose that CETP 
has a role to improve reverse cholesterol transport and glucose metabolism in women.	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Figure 1.1: Schematic of CETP function. CETP facilitates the movement of lipids 
between lipoproteins. Specifically, CETP promotes the flux of CE from HDL to ApoB 
containing lipoproteins LDL/VLDL and TG from LDL/VLDL to HDL. 
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The structure of CETP defines its function 
The function of CETP is tightly linked to its protein structure. CETP facilitates the 
exchange of lipids between lipoproteins by forming a connection between two 
lipoproteins, typically HDL and either LDL or VLDL. Structurally, CETP consists of three 
distinct regions: an N-terminal beta-barrel domain that interacts with HDL, a C-terminal 
domain that interacts with LDL/VLDL, and an internal structure that creates a 
hydrophobic pocket (Fig. 1.2) [132, 133]. The N and C terminal ends of CETP attach to 
lipoproteins and create pores through which lipids can move into the hydrophobic tunnel 
created by the internal structure of CETP. The terminal ends of CETP serve to 
specifically recognize HDL and LDL. Both the N and C terminal domains are highly 
conserved across species, and mutation studies have identified locations in the 
terminals of CETP that are required for lipoprotein binding activity [134, 135]. Once 
attached to the lipoprotein, the ends of CETP penetrate the lipoprotein and form a pore 
through which lipids can move into the central hydrophobic pocket. CETP completely 
penetrates the phospholipid bilayer of HDL, reaching the core of the lipoprotein, while it 
incompletely penetrates the phospholipid bilayer of LDL [136]. CETP activity usually is a 
heteroexchange of lipids, resulting in a one-for-one exchange of TG and CE [137]. In 
what became known as the shuttle hypothesis, CETP was initially thought to function by 
accepting lipids from one lipoprotein, detaching, and then binding to a second 
lipoprotein where it released the bound lipids [138]. More recently, however, a growing 
body of evidence supports the CETP tunnel hypothesis, which proposes that CETP 
docks two lipoproteins together and allows for movement of lipid through the 
hydrophobic core [139]. CETP’s selectivity for specific lipoproteins and its ability to 
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penetrate the lipoprotein surface support the tunnel hypothesis. Regardless of which 
hypothesis reflects the true nature of CETP function, CETP has a physical structure that 
allows for it to selectively target lipoproteins and promote exchange of lipids between 
them. 
 
Intracellular role of CETP 
In addition to its role in serum, CETP has intracellular roles in the trafficking and 
storage of lipids, especially in adipocytes. Expression of CETP in cultured cells resulted 
in an increase in cholesterol uptake that was not affected by the inhibition of 
extracellular CETP using an anti-CETP antibody, suggesting that intracellular CETP 
expression is sufficient to alter cholesterol uptake [140]. Knockdown of CETP in 
adipocytes, which normally express CETP resulted in a 4-fold increase in CE content 
and a 50% reduction in TG content. The knockdown of CETP appeared to alter 
intracellular trafficking of CE and TG, with a large decrease in newly synthesized CE 
and TG in lipid storage droplets and a corresponding increase in these lipids in the 
endoplasmic reticulum [141]. A separate study in cultured hepatocytes showed that 
CETP overexpression or inhibition did not have a significant effect on uptake of CE 
[142]. Overall, these studies suggest that intracellular CETP has a significant effect on 
intracellular lipid trafficking but a non-significant effect on CE uptake from outside the 
cell. The intracellular effect of CETP in the liver is not known. I propose that the major 
effects of CETP on metabolism are related to serum transfer of lipids between HDL and 
LDL and their delivery to the liver. 
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Figure 1.2: Structure of CETP A) Diagram of CETP protein structure highlighting the 
N-terminal (green), C-terminal (yellow), and linker (red) domains of the protein. Two 
cholesteryl esters are shown in the interior hydrophobic pocket (magenta and cyan). B) 
90 degree rotation of the protein providing an alternate view of the protein. Diagram 
from [133]. 
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Insights from clinical studies of CETP 
Because of its important role in lipoprotein metabolism, CETP has received a 
significant amount of focus from clinical and basic research. Since CETP reduces HDL 
and increases LDL cholesterol, it was thought that CETP activity would clearly have 
deleterious effects on cardiovascular health. Exploration of the effect of CETP on 
human health, however, has revealed a more complex role for CETP. Human genetic 
studies have explored the relationships between polymorphisms in the CETP gene and 
various indicators of human health. These studies, however, appear to have raised 
more questions than they have answered. Additionally, the failure of CETP inhibitor 
drugs to reduce risk of CHD has suggested that CETP has additional roles in 
metabolism beyond affecting HDL level. Finally, studies of CETP in humans have 
shown a sexual dimorphism in the role of CETP in metabolism and suggest a beneficial 
effect on reverse cholesterol transport and glucose homeostasis in women. The 
questions raised about CETP through human studies have provided an important basis 
for my dissertation work.  
 
Studies of genetic polymorphisms in the CETP gene  
Studies of human genetics have identified interactions among genetic variants 
that affect CETP activity and insulin sensitivity and cardiovascular risk. Unfortunately, 
these studies have raised more questions than they have answered about the role of 
CETP in health and disease, as the correlations between CETP polymorphisms and 
disease have not been consistent across studies in different populations, suggesting a 
more complex role for CETP than simply negatively impacting health. 
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The CETP gene has an important single nucleotide polymorphism (SNP) at the 
Taq1B site in intron 1. A substitution from guanine to adenine at the Taq1b site is known 
as the B2 variant, whereas the presence of guanine is indicated by the B1 variant. 
Approximately 65% of humans possess at least one copy of the B2 allele. In a study of 
Taq1B polymorphisms in diabetic patients, patients homozygous for B1 showed the 
highest levels of CETP and lowest levels of HDL, whereas those homozygous for the 
B2 polymorphism showed reduced CETP mass and higher levels of HDL.  Overall, the 
B2 polymorphism is associated with lower levels of CETP and higher levels of HDL in 
serum [143]. The Taq1b B1 and B2 polymorphisms of CETP, therefore, have been of 
interest to human genetics researchers as a way to study the effects of variable CETP 
levels on human health. Based on these studies, it appears that the sex and ethnicity of 
the study population have a significant effect on whether CETP activity has a beneficial, 
deleterious, or insignificant effect on human health.	  
 Several genetic studies have identified a correlation between the CETP Taq1b 
B1 polymorphism and increased risk of disease. Across multiple genetic studies ,the B1 
polymorphism was consistently associated with lower levels of circulating HDL. A study 
from the Framingham Offspring population showed that the B1 polymorphism was 
correlated with reduced HDL [144].  Additionally, studies performed in people from 
Chinese, Iranian, and Tunisian populations have shown a correlation between the B1 
genotype and reduced HDL as well as increased risk of CHD [145-147]. A study in an 
Iranian population also identified a correlation between the B1 allele and increased risk 
of CHD that was independent of plasma HDL level [148]. Interestingly, a study of an 
American population with pre-existing coronary artery disease showed that while the 
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presence of the B1 allele correlated with reduced serum HDL, it did not have a 
significant correlation with heart attack events. The study showed, however, that people 
with the B2 allele benefited more from statin therapy, with a larger reduction in heart 
attacks seen in the B2 group than the B1 group when they were both put on statin 
therapy [149]. Finally, a study in a French population showed that the B1 allele was 
correlated with higher incidence of CHD. Additionally, the study showed that people 
homozygous for the B1 allele had an elevated risk of sudden death from cardiovascular 
causes not related to fatal stroke or myocardial infarction (MI) [150]. Overall, a 
significant body of evidence suggests that the B1 allele correlates with higher CETP 
activity and reduced serum HDL. These changes in serum HDL do not correlate with 
increased CHD risk in all studies. 
The Taq1b B1 polymorphism does not always correlate with increased risk of 
disease compared to the B2 polymorphism, and the correlation of the B1 polymorphism 
with increased risk does not appear to be uniform across study populations of differing 
ethnicities, particularly in Asian populations. A study in a Singaporean population 
consisting of people from Chinese, Malaysian, and Indian ethnic backgrounds showed 
that the Taq1b B2 had a protective effect against CHD in the Chinese population [151]. 
The same study, however, did not observe an effect of the B2 polymorphism on risk of 
CHD in the people of Malaysian and Indian ethnicity [151]. A different study in an Indian 
population, however, showed a correlation between increased risk of CHD and the B1 
polymorphism [152]. Overall, genetic studies of CETP have shown that CETP has a 
significant effect on serum lipoproteins, with increased CETP activity correlating with 
reduced HDL. While reduced HDL is a classic risk factor for increased risk of CHD, 
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genetic variation in CETP that is correlated with reduced HDL does not always correlate 
with increased risk of CHD. Further study of CETP is therefore required to determine its 
role in whole-body metabolism. 
 
CETP inhibitor drugs 
Since CETP correlates with decreased HDL, CETP inhibition became a popular 
target of drug development efforts that aimed to increase HDL levels and reduce risk of 
CHD. The studies performed on the development and testing of these drugs have 
provided further insight into the role of CETP in CHD but have also raised additional 
questions about the linkage between HDL levels and risk of CHD. Although CETP 
inhibitors have proven effective at inhibiting CETP activity and elevating serum HDL 
level, none of the inhibitor drugs tested to date, specifically Torcetrapib and Dalcetrapib, 
have demonstrated clinically meaningful efficacy in reducing CHD risk. Two other CETP 
inhibitors, Anacetrapib and Evacetrapib, are currently in phase III clinical trials. The lack 
of demonstrated clinical efficacy by this class of drugs suggests that CETP may have 
underappreciated effects on cardiovascular health that are independent of its effect on 
HDL levels.	  
 Torcetrapib is the most famous CETP inhibitor and the first to enter phase III 
clinical trials. The drug was considered a failure after the phase III trial was halted due 
to an increase in myocardial infarction events in the treatment group compared to 
placebo [153]. Torcetrapib binds CETP in a 1:1 ratio and increases the affinity of CETO 
for HDL, forming a nonproductive complex that inhibits all of the lipid transfer functions 
of CETP [154]. While treatment with Torcetrapib reduced LDL cholesterol by 25% and 
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raised HDL cholesterol by 70%, the hazard ratio for cardiovascular events was 1.25 in 
the Torcetrapib treated patients compared to the placebo control group. This lack of 
efficacy suggests that there is a role for CETP that may be independent of its effects on 
HDL amount. The failure of Torcetrapib was attributed to off-target effects of the drug to 
increase blood pressure that was associated with increases in aldosterone and 
corticosterone [155]. The effects of Torcetrapib on CETP activity, however, have not 
been ruled out as a potential deleterious effect on cardiovascular health. Since CETP 
inhibition significantly increased HDL, it was expected that it would correlate with 
reduced risk of CHD. Surprisingly, inhibition of CETP increased risk of death from CHD.   
 Other drugs that do not have effects on the aldosterone system, such as 
Dalcetrapib, have also been investigated in clinical trials. Dalcetrapib was the first small 
molecule inhibitor of CETP to be developed, although it entered phase III clinical trials 
several years after Torcetrapib. Dalcetrapib is a less potent inhibitor of CETP that 
covalently binds CETP. Both Torcetrapib and Dalcetrapib increase affinity of CETP for 
HDL, and they compete with each other for binding CETP, suggesting that they target 
similar domains of CETP [156]. Dalcetrapib treatment of hamsters resulted in a net 
increase in reverse cholesterol transport (RCT) as indicated by tracer efflux from 
radiolabeled cholesterol-laden macrophages to feces in the form of both neutral sterols 
and bile acids [157]. In contrast, clinical studies of Torcetrapib did not show an increase 
in fecal sterol secretion in a study of human subjects [158]. When bound to CETP, 
Dalcetrapib induces a conformational change in the CETP protein that interferes with its 
ability to bind LDL/VLDL but maintains it ability to bind HDL [157]. In this model, 
Dalcetrapib allows for CETP-mediated exchange of lipids between HDL particles and 
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promotes the lipidation of nascent HDL, increasing HDL levels and promoting reverse 
cholesterol transport[157].  
In contrast to Torcetrapib, Dalcetrapib does not alter the aldosterone system and 
has no effect on blood pressure [159]. Similar to Torcetrapib, Dalcetrapib treatment 
significantly increases HDL levels by about 30%. Clinical trials of Dalcetrapib, however, 
did not show a clinically meaningful reduction in CHD risk [9]. Since Dalcetrapib does 
not alter blood pressure, its failure to protect against CHD risk suggests that the CETP 
inhibitors as a class of drugs may not be effective clinically despite their ability to 
increase HDL cholesterol levels. The failure of CETP inhibitors to protect against CHD 
despite increasing HDL concentration illustrates a need to better understand the role of 
CETP in metabolism. CETP has effects on metabolism beyond its role in HDL 
concentration that have recently been identified in human and animal studies. 
 
Sex-specific role for CETP activity in humans  
Studies of CETP in humans suggest that CETP has differential effects in men 
and women, specifically with regards to glucose metabolism. In men, studies suggest a 
neutral or harmful effect of CETP on glucose homeostasis. An association study in men 
showed a correlation between high levels of CETP activity and markers of insulin 
resistance [160]. Additionally, an insulin clamp study performed in men showed no 
correlation between CETP activity and insulin sensitivity [161]. A post-hoc analysis of 
the ILLUMINATE CETP inhibitor trial showed that diabetic patients treated with the 
Torcetrapib had a modest reduction in hemoglobin A1c [161]. This study involved 70% 
men and only examined individuals with diabetes and CHD. 
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Reciprocally, studies in females suggest beneficial effects of CETP on 
cholesterol efflux and glucose metabolism. Higher CETP activity is associated with 
increased transfer of CE from macrophages to HDL in women but not men [12, 131]. 
This improved RCT capacity with increased CETP was independent of HDL cholesterol 
[12]. In women, CETP polymorphisms that increase CETP activity correlated with 
reduced risk of ischemic heart disease [162]. Higher CETP activity is associated with 
improved glucose metabolism after roux-en-Y gastric bypass in women only [13, 163]. 
Overall, studies of CETP in humans have revealed a much more complex role for 
CETP with regards to CHD than a simple effect on circulating HDL levels. The effect of 
CETP on risk of CHD appears to be influenced by ethnicity based on polymorphism 
studies. Additionally, the failure of CETP inhibition to reduce heart attack despite 
increasing HDL suggests that CETP’s lipid transfer activity may not directly result in 
increased CHD risk. Finally, studies in humans have suggested a sex-specific role for 
CETP, with CETP activity actually correlating with improved health outcomes in women. 
CETP requires further study to fully understand its effects on human health.  
 
Regulation of CETP in humans  
CETP levels are highly variable in humans [164]. Serum CETP levels are known 
to be increased by obesity [165] and estrogen [166], and CETP expression is acutely 
suppressed by insulin [167]. Human CETP is highly regulated at the transcriptional level 
[168, 169]. The human CETP promoter is regulated by SREBP1a [170], LXR [171], 
LRH-1 [172], and RXR [173]. Overall, CETP expression appears to be linked to 
intracellular cholesterol content, which activates SREBP1a and LXR, both of which have 
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response elements in the CETP promoter [170, 171]. The observation that expression 
of the CETP gene is induced by dietary cholesterol is consistent with this model [174]. 
Estrogen has been shown to interact with SREBP1a signaling [175], which could be the 
mechanism by which estrogen upregulates CETP levels.    
Because of the variability associated with the CETP gene under control of the 
human promoter, I chose to use a transgenic mouse model that expresses CETP under 
control of a constitutive promoter. Mice do not naturally express CETP, so transgenic 
expression of CETP is required to study CETP in mice. The particular mouse strain that 
I used expresses a simian CETP gene under control of the metallothionein promoter 
known as UCTP-20. This mouse line was generated in the early 1990s with the goal of 
understanding the contribution of CETP to the primate/human lipoprotein profile [176]. 
The transgenic mouse model expresses CETP in all tissues except lung and spleen, but 
the levels of CETP RNA are by far the highest in the liver, followed by the brain and 
heart [176].  The CETP transgenic mice show a more human-like lipid profile, with 
increased cholesterol in ApoB containing lipoproteins and decreased cholesterol in 
ApoA containing lipoproteins compared to WT mice [176]. When fed a high-fat/high-
cholesterol diet, the CETP-expressing mice showed an increase in total cholesterol 
[176]. A second study of the same transgenic mice showed increased atherosclerotic 
lesions in aortas of the CETP-expressing mice when fed a high-fat/high-cholesterol diet 
[177]. I assert that these mice are an appropriate model to test the contribution of a 
constant level of CETP on whole-body metabolism. Since human CETP is regulated by 
diet, insulin, and estrogen, I wanted to use a model that would have consistent CETP 
activity during high-fat feeding, hyperinsulinemic clamps, and between sexes.  
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Beneficial role of CETP on reverse cholesterol transport: Insights from model 
organisms 
Recent work in both model organisms and humans has suggested that CETP 
has a beneficial role to promote RCT and thereby promote bile acid secretion. Bile acids 
have recently been shown to have beneficial effects on glucose metabolism; therefore, 
CETP may be a factor that promotes metabolic health.  
The study of CETP in mice has required development of transgenic mice or viral 
expression of CETP. Expression of CETP in mice has demonstrated that CETP 
promotes RCT in a manner that is SR-B1 independent but LDLR dependent. 
Expression of CETP in an SR-B1 knockout mouse model almost completely reversed 
the hypercholesterolemia associated with SR-B1 deficiency [10], suggesting that CETP 
is able to promote RCT independently of SR-B1, which is the primary method of HDL 
uptake by the liver. In another study, viral expression of CETP in mice increased efflux 
of radiolabeled cholesterol from macrophages to feces in SR-B1 knockout mice but not 
LDLR knockout mice, indicating that CETP promotes RCT in an LDL receptor-
dependent manner [11]. The activity of CETP to promote movement of cholesterol from 
HDL to LDL likely increases the RCT through hepatic cholesterol uptake from LDL 
through LDLR. The increase in radiolabeled cholesterol to feces in the CETP-
expressing animals suggests that CETP may increase gut bile acid content, as 
cholesterol that is taken up by the liver is largely excreted in the form of bile acids (Fig. 
1.3). Recent studies have suggested that bile acids can be signaling molecules that 
improve glucose metabolism. Therefore, the ability of CETP to promote RCT and 
increase bile acid content may improve whole-body glucose homeostasis.	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Figure 1.3: CETP promotes reverse cholesterol transport by increasing LDL-
mediated delivery of CE to the liver.  CETP expression mediates flux of CE from HDL 
to LDL. CETP promotes reverse cholesterol transport by increasing delivery of CE to 
the liver through LDL receptor. This process causes increased secretion of bile into the 
gut, as cholesterol is converted to bile in the liver and secreted into the gut. 
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 Bile acid signaling improves glucose metabolism 
In addition to their role in digestion, bile acids are signaling agents that regulate 
pathways important for glucose metabolism in tissues including liver, adipose tissue, 
and muscle. Bile acids improve glucose metabolism by inhibiting hepatic 
gluconeogenesis, promoting hepatic glycogen storage, and promoting energy 
expenditure in brown adipose tissue and skeletal muscle.  Because CETP has been 
shown to increase RCT and bile acid production, I propose that CETP may potentially 
have a protective effect against the development of metabolic syndrome with obesity.  
Bile acids signal through three major pathways to alter glucose metabolism in 
liver, adipose tissue, and muscle (Fig. 1.4). 1) Bile acids promote the secretion of the 
enterokine fibroblast growth factor 15 (Fgf15), which signals to the liver to suppress 
hepatic glucose production. 2) Bile acids themselves act as ligands of Fxr in the liver. 3) 
Bile acids activate the g-protein coupled bile acid receptor (GPBAR1 also known as 
TGR5) in brown adipose tissue and muscle. These pathways combine to promote 
healthy glucose metabolism by suppressing hepatic gluconeogenesis and promoting 
muscle glucose uptake. 
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Figure 1.4: Bile acids signal to alter metabolism in liver, adipose tissue, and 
muscle.  Bile acids recirculate from the gut to the liver and serve as a ligand for Fxr, 
which induces Shp expression, a transcriptional co-repressor that downregulates genes 
the products of which promote hepatic gluconeogenesis. In the gut, bile acids induce 
production of FGF15, which signals to the liver through Fgf4r to promote glycogen 
storage and downregulate genes the products of which promote gluconeogenesis. A 
small amount of bile acids escape the entero-hepatic circulation into the systemic 
circulation. Bile acids can signal through Gpbar1 to promote glucose disposal in brown 
adipose tissue and skeletal muscle. 
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Bile acids signal through Fgf15 to alter hepatic glycogen storage and 
gluconeogenesis 
The effect of bile acids on hepatic insulin sensitivity is in part mediated by Fgf15. 
Fgf15 is produced in ileal enterocytes in response to bile acid signaling through 
farnesoid X receptor (Fxr) [178]. Fgf15 signals to the liver through the fibroblast growth 
factor 4 receptor (Fgf4r) to activate ERK1/2 (Fig. 1.4) [179]. Fgf15 signaling in the liver 
has been shown to promote glycogen storage and reduce gluconeogenesis [14, 15]. 
Fgf15 knockout mice exhibit glucose intolerance and have reduced liver glycogen 
content compared to control mice [14]. Treatment of mice with Fgf15 resulted in 
increased hepatic glycogen synthase and increased phosphorylation of glycogen 
synthase kinase 3α and β. Administration of Fgf15 to mice with streptozotocin-induced 
diabetes normalized hepatic glycogen content to levels of control mice [14]. 
In addition to its ability to promote hepatic glycogen storage, bile acid signaling 
through Fgf15 suppresses hepatic gluconeogenesis. Treatment of lean mice with Fgf15 
results in downregulation of peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC1α), which is a transcription factor central to activating genes 
the products of which control gluconeogenesis [15]. Consistent with this result, G6pc 
and Pck gene expression was decreased in mice treated with Fgf15. Adenoviral 
overexpression of Fgf15 similarly reduced gene expression for factors that control 
gluconeogenesis and also repressed hepatic gluconeogenesis, TCA cycle flux, and fatty 
acid oxidation [15]. In contrast, Fgf15 knockout mice exhibit hyperglycemia, increased 
gene expression for G6pc and Pck, and increased levels of gluconeogenesis during the 
fed state compared to control mice [15]. Overall, Fgf15 has emerged as an important 
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new enterokine factor that allows for bile acids to signal to the liver to promote storage 
of glucose as glycogen and suppress hepatic gluconeogenesis. Fgf15 acts 
independently of insulin through the ERK signaling pathway and may be a factor that 
can improve insulin sensitivity in insulin resistant people. 
 
Bile acids signal through hepatic Fxr to suppress gluconeogenesis    
Bile acids are ligands for the nuclear transcription factor Fxr, which induces 
expression of small heterodimer partner (Shp) (Fig. 1.4) [180, 181]. Fxr is required for 
normal glucose metabolism in the liver, and Fxr knockout mice exhibit a number of 
metabolic irregularities including fatty liver, elevated serum free fatty acids, elevated 
serum glucose, and insulin resistance. Feeding mice a 1% cholic acid diet, which is an 
agonist for Fxr caused a significant decrease in RNA levels for Pck, Ppargc1a, and 
G6pc, genes the products of which promote hepatic gluconeogenesis. These effects 
were not observed in Fxr knockout mice, indicating that Fxr is required for the 
suppressive effects of bile acids on gluconeogenesis [182]. The effect of the cholic acid 
treatment on metabolism is likely due to a combination of direct Fxr signaling in the liver 
and indirect signaling through Fgf15, as production of Fgf15 is activated through Fxr 
signaling in the gut.  
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Bile acids signal through Gpbar1 to increase energy expenditure and glucose 
oxidation 
Bile acids signal through a third pathway to muscle and adipose tissue through 
the G-protein coupled bile acid receptor Gpbar1 (Fig 1.4). Addition of the bile acid cholic 
acid to a high-fat diet resulted in decreased adiposity compared to high fat diet (HFD) 
without added cholic acid [17]. The authors of this study reported that signaling through 
Gpbar1 activates type-2 thyroid deiodinase (Dio2), which leads to increased energy 
expenditure in brown adipose tissue [17]. Further study of Gpbar1 has shown it to have 
a role in regulation of glucose homeostasis. Treatment of diet-induced obese mice with 
a Gpbar1 agonist resulted in increased energy expenditure, reduced levels of hepatic 
fat, and decreased adiposity. Additionally, treatment of both diet-induced obese mice 
and db/db mice with a Gpbar1 agonist improved glucose tolerance as measured by oral 
glucose tolerance tests. Hyperinsulinemic clamps in diet-induced obese mice treated 
with a Gpbar1 agonist showed that activation of Gpbar1 improves insulin sensitivity. 
Studies of isolated brown adipocytes treated with the Gpbar1 agonist showed that 
mitochondrial oxygen consumption was increased by Gpbar1 activation [16]. 
Additionally, bile acid signaling to Gpbar1 in intestinal L-cells caused increased 
secretion of Glp1, which is known to promote glucose stimulated insulin secretion [16]. 
Activation of Gpbar1 by bile acids is protective against HFD-induced glucose 
intolerance and insulin resistance likely due to its ability to promote glucose disposal. 
Based on these studies, I propose that factors that increase bile acid production or 
secretion, such as CETP, might be protective against the effect of obesity on glucose 
metabolism and insulin sensitivity.  
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Bile acid treatment improves insulin sensitivity in obese humans 
Bile acids also appear to have a significant effect on glucose metabolism in 
humans. Obese humans treated with a four- week oral course of the bile acid 
tauroursodeoxycholic acid (TUDCA) showed improved hepatic insulin sensitivity as 
defined by glucose production during a hyperinsulinemic clamp. Additionally, the 
TUDCA-treated subjects showed an increase in clamp glucose rate of disappearance, 
suggesting improved muscle insulin sensitivity [183]. The TUDCA-treated subjects also 
showed improvement in muscle insulin signaling, with higher levels of insulin receptor 
substrate tyrosine phosphorylation and increased levels of Akt serine phosphorylation. 
This study demonstrates that bile acid treatment improves insulin sensitivity in obese 
humans and that the benefits of bile acid signaling are not restricted to the mouse. 
 
Obesity decreases exercise capacity 
Weight loss is the best method to reverse the effects of obesity. One method that 
can help people lose weight is increased physical activity. Unfortunately, exercise 
capacity is known to decline with obesity, and therefore losing weight through exercise 
becomes more difficult, creating a vicious cycle. Exercise capacity is defined as the 
maximal amount of physical exertion that a person can sustain, and it is frequently 
defined clinically using a treadmill test. A study of people with pre-existing diabetes 
showed that BMI and waist circumference negatively correlate with exercise capacity, 
demonstrating the link between obesity and impaired exercise capacity [4]. Mechanisms 
that might help improve exercise capacity could help to treat obesity and improve quality 
of life for obese people. 
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Exercise capacity is extremely important to overall health, as a study of patients 
referred for clinical exercise testing showed that level of physical fitness inversely 
correlated with death from all causes. In fact, exercise capacity was a stronger predictor 
of death than established cardiovascular risk factors such as hypertension, smoking, 
and diabetes [184]. A second study of exercise capacity in diabetic men showed that 
reduced exercise capacity was predictive of mortality in a manner that was independent 
of BMI [185]. These results suggest that fitness in the form of exercise capacity may be 
more important in preventing deaths than previously identified factors such as 
hypertension, smoking, obesity, and diabetes. Mechanisms that might improve exercise 
capacity even in the context of obesity are therefore important to study.  
 
Exercise capacity depends on muscle substrate oxidation 
Exercise capacity depends on multiple different factors throughout the body, but 
all are related to the ability of muscle mitochondria to efficiently oxidize substrate to 
produce ATP.  Exercise capacity depends both on central factors such as the ability of 
the lungs to extract oxygen and the ability of the heart to pump oxygenated blood to 
muscle tissue [186, 187]. Additionally, peripheral factors such as the ability of oxygen to 
diffuse from blood vessels to muscle, the density of capillaries in the muscle, and the 
ability of mitochondria to effectively perform oxidative phosphorylation all contribute to 
exercise capacity [188, 189]. In addition to delivery of oxygen, exercise capacity also 
depends on oxidation of substrate. At lower levels of exercise intensity (less than 50% 
of maximal capacity), the majority of substrate used for exercise is lipid. At higher levels 
of exercise intensity, carbohydrate becomes the preferred substrate. A study of men 
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running on a treadmill at a fast versus slow pace showed that nearly 100% of the 
energy expenditure was from carbohydrate in the fast group compared to 80% in the 
slower-paced group[190].  Therefore, mechanisms that improve muscle glucose 
oxidative capacity might help to improve exercise capacity, as improved ability to utilize 
glucose in muscle might lead to increased tolerance for higher intensity exercise.  
Studies have suggested that bile acid signaling through Gpbar1 increases 
muscle glucose utilization by improving mitochondrial oxidative capacity. Since CETP is 
known to promote RCT and bile acid production, I propose that CETP expression might 
increase exercise capacity by improving muscle mitochondrial oxidative capacity. 
 
Summary 
 Obesity is a serious health challenge, as it correlates with risk of CHD and 
diabetes. Mechanisms that improve metabolic health in obese people might help to 
delay or prevent the development of these diseases. Cholesteryl ester transfer protein 
may be a previously underappreciated factor that could promote healthy metabolism in 
obesity. CETP was previously thought to be harmful due to its effects on lipid profile, but 
inhibition of CETP has not proven to be an effective strategy to prevent CHD. Further 
study of CETP is therefore required to fully understand its role in metabolism. Studies in 
humans have suggested a sexual dimorphism related to CETP and have shown that 
CETP might be a neutral factor in men but have a positive effect on RCT and glucose 
homeostasis in women.  Recent research in animal models has demonstrated that 
CETP can promote RCT and secretion of cholesterol into the gut in the form of bile 
acids. Bile acids have been shown to activate signaling pathways in gut, liver, adipose 
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tissue, and muscle that lead to improved glucose homeostasis (Fig. 1.4). Bile acid 
signaling also leads to improved mitochondrial function in muscle, which is an important 
factor in exercise capacity. Therefore, I propose that CETP is a positive factor that might 
protect against the development of insulin sensitivity and exercise intolerance with 
obesity.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Animals and diets 
CETP transgenic mice on a C57BL/6 background were purchased from Jackson 
Laboratories (C57BL/6-Tg(CETP)1Pnu/J, Stock Number: 001929). This strain 
expresses a simian CETP gene under control of the metallothionine promoter [15, 16]. 
All mice were maintained on a standard chow diet until placed on a sucrose-free high fat 
diet (HFD) with carbohydrate content comprised of cornstarch (60% fat, 20% 
carbohydrate, 20% protein, Research Diets D08060104). Mice were 12-14 weeks old at 
onset of diet and were fed HFD for 4 weeks. Body composition was determined on the 
day of study using an mq10 NMR analyzer (Bruker Optics). All procedures were 
performed in accordance with National Institutes of Health Guidelines for the Care and 
Use of Animals and approved by the Institutional Animal Care and Use Committee at 
Vanderbilt University. 
 
Surgical catheterization 
Five to seven days prior to the clamp study, mice received catheters in the 
jugular vein and carotid artery at the Vanderbilt Mouse Metabolic Phenotyping Center. 
Surgeries were performed using aseptic technique, and all surgical instruments and 
other materials were sterilized prior to use. Mice were anesthetized with isoflurane using 
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a vaporization system. To catheterize the carotid artery, a small vertical midline incision 
was made 5mm cephalic to the sternum. The left sternomastoid muscle was exposed 
using forceps, and the carotid artery was separated from connective tissue. Once 
isolated, the cephalic end of the artery was ligated with silk suture, and a second piece 
of suture was loosely knotted on the caudal end of the exposed artery. The blood vessel 
was clamped with micro-serrefine hemostats, and a small incision was made in the 
blood vessel just below the ligated end.  Six cm pieces of silastic flexible plastic tubing 
(0.012” ID) were prepared for use as catheters. The catheter was inserted into the 
carotid artery, and both ligatures were tied to secure the catheter. A second incision 
was made 5 mm to the right of the midline and 2 mm caudal to the first incision. The 
jugular vein was exposed, and a catheter was inserted using a similar procedure to the 
arterial catheterization. Once the two catheters were implanted, free catheter ends were 
tunneled under the skin to the back of the neck, externalized, and sealed with steel 
plugs. All incisions were closed with silk suture. Mice were monitored for health during 
surgical recovery and treated with antibiotics (ceftriaxone) and analgesics 
(ketofen).  Mice were maintained on HFD and were allowed 5-7 days for recovery after 
surgery. Only mice returning to within 10% of pre-surgical body weight were studied. 
Overall, these methods permit arterial sampling and are less stressful than cut-tail 
sampling.  
 
Hyperinsulinemic-euglycemic clamp studies 
To assess insulin sensitivity, a 2-hour hyperinsulinemic-euglycemic clamp study 
was performed on mice fasted for 5 hours. Mice were weighed and then fasted starting 
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between 0800 and 0900h. During the fast, glucose, donor blood, insulin, and 
radiolabeled glucose were prepared. Fifty percent dextrose solution was drawn into a 
3mL syringe for glucose infusion. Donor blood was prepared by collecting 1mL of blood 
from a donor mouse. Blood was then centrifuged, and red blood cells were isolated. 
Red blood cells were washed with heparinized saline, centrifuged, and then 
resuspended in an equal volume of heparinized saline. Donor blood was infused at a 
rate of 2.5 µL/min during the clamp.  Insulin was prepared by diluting U-100 insulin 
tenfold in a 3% saline-donor plasma mixture. Insulin was then diluted based on the 
weight of the mouse to achieve an infusion rate of 4 mU/kg/min at a constant infusion 
rate of 3 µL/min. Fifty µCi of radiolabeled [3-3H] glucose per mouse was dried and 
resuspended in 1 mL of saline. Twenty µL of this solution was saved to determine the 
exact dose of tracer given to each mouse. Glucose, insulin, donor blood, and 
radiolabeled glucose were each attached to a separate infusion pump (Harvard 
apparatus), and all infusions were into the jugular vein. The arterial catheter was flushed 
with heparinized saline prior to the clamp study and used to draw blood for all samples.  
To trace whole-body glucose turnover, a 1.5-µCi bolus of [3-3H] glucose was 
given at t = −90 min (90 mins prior to insulin/glucose infusion) followed by a 0.05 
µCi/min infusion until t=0. The clamp was begun at t = 0 min with a continuous infusion 
of insulin (4 mU · kg−1 · min−1). The [3-3H] glucose infusion was increased to 0.1 µCi/min 
for the remainder of the experiment to prevent changes in specific activity. More recent 
developments in tracer technique suggest mixing the tracer with the non-labeled 
glucose 50/to Euglycemia (100-150 mg/dl) was maintained by measuring blood glucose 
every 10 min by glucometer starting at t = 0 min and infusing 50% dextrose by variable 
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infusion. Hematocrit was measured at t = 0 and t = 90 to determine that there was no 
fall in red blood cell count. Arterial samples to measure plasma hormones and glucose 
turnover were taken at t=60, and during the steady-state period at 80, 90, and 100 min. 
The steady state period is defined by a constant state of glucose infusion, indicating that 
the rate of glucose production equals the rate of glucose removal.   At 120 min, mice 
were sacrificed and tissues were collected and frozen in liquid nitrogen. Insulin 
sensitivity index (SI) was calculated by dividing the steady-state glucose infusion rate in 
mg/kg*min by the steady state insulin concentration in mU/mL to yield SI in 
(mg*mL)/(kg*min*mU) [191].  
 
Tracer analysis 
[3-3H] glucose was infused to measure glucose rate of appearance 
(EndoRa)  and glucose rate of disappearance (Rd). Levels of radioactivity were 
determined by scintillation counting on a Perkin-Elmer TriCarb 2390 scintillation counter 
and expressed in disintegrations per minute (DPM). Glucose turnover is calculated 
using the body weight of the mouse, the glucose infusion rate, the tracer infusion rate, 
and the specific activity of plasma glucose at each time point.  The tracer infusion rate is 
determined by scintillation counting of the tracer infusate and the rate of tracer 
infusion.  A 10 µL of a 1:200 dilution of the tracer infusate was dried down and counted 
to obtain the Chemical Standard Evaporated (CSE). The tracer infusion rate in 
dpm/kg/min is therefore equal to: 
!"#$%"  !"#$%!&"  !"#$  (!"#/!"/!"#)   = (!"#$  !"#$ ∙ !"# ∙ 20)(!"#$  !"#$ℎ!  /1000)    
Specific activity (SA) is defined as the ratio of tracer to tracee and is measured in 
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dpm/mg. To calculate plasma SA, the plasma glucose concentration and the plasma [3-
3H] glucose concentration are required. Plasma samples are treated with Ba(OH2) and 
Zn2SO4 to de-proteinate the sample. Samples are then evaporated and counted on a 
scintillation counter.  A sample of the infusate is treated and counted in the same 
manner to provide the Chemical Recovery Standard (CRS). Plasma specific activity is 
therefore: 
!"#$%&%$  !"#$%$#&  (!"#/!")   =   !"#$%#  !"#10 ∙ !"#!"# ∙ 1000!"#$%#  !"#$%&'/100   
Glucose turnover in mg/kg/min can therefore be represented by: !"#$%"  !"#$%!&"  !"#$  (!"#/!"/!"#)  !!"#$"  !"#$%&'  !"#$%&%$  !"#$%$#&  (!"#/!")    
The endogenous glucose rate of appearance (Endo Ra) is equal to the glucose turnover 
rate minus the exogenous glucose infusion rate  
 
Western blots 
Whole cell protein extracts were performed on frozen liver and muscle tissue 
using a T-PER protein extraction kit (Pierce bioscience). Protein concentration in 
extracted samples was measured using a Pierce BCA protein assay kit. Western 
blotting was performed using precast 4-12% bis-tris gels (Life Technologies) in an 
Invitrogen Novex mini-cell chamber. Twenty µg of protein was loaded per sample. 
Protein was transferred from the gel onto nitrocellulose membrane and then blocked 
using Odyssey blocking buffer. Following blocking, membranes were treated with 
primary antibody, washed with tris buffered saline, treated with secondary antibody, 
washed, and then imaged. Primary antibodies for Akt, P-Akt (Ser473), Erk1/2, and P-
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Erk1/2 (Thr202/Tyr204) were purchased from Cell Signaling Technology. Antibodies for 
actin and ERα were purchased from Santa Cruz Biotechnology. IR-Dye 800 anti-rabbit 
secondary antibody (LI-COR Biotechnology) was used for band visualization on an 
Odyssey imaging system. 
 
Serum analysis 
Serum insulin values were determined using a commercial ELISA kit (Millipore). 
CETP activity was measured using a commercially available kit (Roar Biochemical RB-
CETP). Serum TG and cholesterol levels were measured using commercially available 
kits (Raichem). Serum estradiol was quantified using a commercially available kit 
(Calbiotech). Serum leptin, adiponectin, and IL-6 were quantified by luminex assay at 
the Vanderbilt Hormone Assay & Analytical Services Core. 
 
Gene expression 
RT-PCR was used to measure gene expression. RNA was extracted from tissues 
(RNeasy Mini, Qiagen) and cDNAs were synthesized using 1 µg RNA template (iScript 
cDNA synthesis kit, BioRad).  qPCR was conducted using SYBR Green JumpStart Taq 
ReadyMix (Sigma) in a 20 µl reaction with 400nM final primer concentration.  Reactions 
were carried out for 30 cycles of 95°C for 10s, 58°C for 45s, and 72°C for 60s (MyIQ, 
Bio Rad). Ct values were analyzed using the efficiency corrected Pfaffl method and 
were normalized to cyclophilin A. Fold change was determined relative to fasted WT 
littermates. Primer sequences are provided in Table 2.1. 
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Metabolite analysis 
Metabolite analysis was performed by Metabolon Inc. (Durham NC). Briefly, 
aqueous and organic metabolites were methanol extracted and then analyzed both by 
LC/MS and GC/MS. Metabolites were identified by comparison to a library of known 
compounds and normalized to internal standards. Welch’s two-sample t-test and an 
estimate of the false discovery rate (q-value) were used to take into account the multiple 
comparisons that normally occur in metabolomic-based studies. One animal was 
excluded as an outlier for hepatic bile acid data, as the gallbladder was ruptured during 
tissue collection. 
 
Gut bile acid analysis 
Bile acids were extracted from ileum tissue by ethanol extraction using a dounce 
homogenizer. Bile acids were quantified using a commercially available enzymatic 
assay (Crystal Chem). 
 
Indirect calorimetry 
Indirect calorimetry was performed on HFD-fed female CETP and WT littermates 
using a Promethion system in the Vanderbilt MMPC (Sable Systems International). The 
system allows for measurement of VO2, VCO2, food intake, feeding behavior, heat 
generation and activity level. Mice were individually housed in the system for a period of 
4 days during which measurements were taken. The facility uses a standard 12 h 
light/dark cycle, and measurements for light and dark phases are reported separately. 
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Exercise studies  
Exercise studies were performed in 12-week old female CETP transgenic mice 
and their non-transgenic littermates. Mice were fed a standard chow diet until the date 
of the first exercise study, after which they were fed a sucrose-free HFD with 
carbohydrate content comprised of cornstarch (60% fat, 20% carbohydrate, 20% protein, 
Research Diets D08060104). Animals were subjected to an exercise tolerance test 
every 2 weeks after the beginning of HFD. One week before the first exercise study, 
animals were acclimated to treadmill running. In the exercise tolerance test, mice were 
individually placed on an enclosed treadmill attached to an oxymax oxygen analyzer 
and run at an initial speed of 10 m/min at a 0% grade. Every 3 minutes, speed was 
increased by 4 m/min. The study was continued until the animal was exhausted, as 
indicated by remaining on the shock pad at the rear of the treadmill. A total of 4 exercise 
tolerance tests were performed at 0, 2, 4, and 6 weeks of HFD. 
After 10 total weeks on HFD, mice were subjected to a single bout exercise test. 
Mice were run at a constant speed of 10 m/min for 15 minutes. Immediately before the 
study, a bolus of 2-deoxyglucose was administered to trace glucose uptake by muscle 
tissue. Following the exercise study, animals were sacrificed and tissues were collected 
and flash frozen. 
 
Statistics 
Data are presented as mean ± SEM. Data were analyzed by student’s t-test, 1-
way ANOVA using Tukey’s post-test, or 2-way ANOVA using Bonferoni post-test as 
appropriate. p < 0.05 is considered statistically significant. 
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Sample sizes were chosen to be able to reject the null hypothesis that the 
population means of the experimental and control groups are equal with probability 
(power) 0.8.   The Type I error probability associated with this test of this null hypothesis 
is 0.05. Power calculations were performed using PS Power and Sample Size 
Calculations, Version 2.1.30 
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Table 2.1: RT-PCR Primer sequences 
  
 
Primer Sequence 
cpt1b_F TCTAGGCAATGCCGTTCAC 
cpt1b_R GAGCACATGGGCACCATAC 
dio2_F CTTCCTCCTAGATGCCTACAAAC 
dio2_R GGCATAATTGTTACCTGATTCAGG 
fxr_F TCCGGACATTCAACCATCAC 
fxr_R TCACTGCACATCCCAGATCTC 
g6pc_F CTGCAAGGGAGAACTCAGCAA 
g6pc_R GAGGACCAAGGAAGCCACAAT 
hk2_F GGAACCCAGCTGTTTGACCA 
hk2_R CAGGGGAACGAGAAGGTGAAA 
hnf4a_F ACCAAGAGGTCCATGGTGTTT 
hnf4a_R GTGCCGAGGGACGATGTAG 
lrh1_F TGGGAAGGAAGGGACAATCTT 
lrh1_R CGAGACTCAGGAGGTTGTTGAA 
ppia_F CGATGACGAGCCCTTGG 
ppia_R TCTGCTGTCTTTGGAACTTTGTC 
shp_F CGATCCTCTTCAACCCAGATG  
shp_R AGGGCTCCAAGACTTCACACA  
 !
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CHAPTER III 
 
CHOLESTERYL ESTER TRANSFER PROTEIN PROTECTS AGAINST INSULIN 
RESISTANCE IN OBESE FEMALE MICE 
 
Introduction 
Insulin resistance associated with obesity leads to metabolic syndrome, diabetes, 
and increased risk of developing CHD. These risk factors are reduced by weight loss; 
however, weight reduction regimens rarely result in long-term maintenance of reduced 
body weight [1, 2]. Activation of pathways that improve insulin sensitivity would be an 
attractive alternative to weight loss as a way to prevent complications of obesity.  One 
important pathway that has recently been linked to insulin sensitivity is bile acid 
signaling to liver and muscle [15, 16, 183]. Activation of pathways that promote bile 
production and secretion may improve insulin sensitivity in the setting of obesity. CETP 
is a lipid transfer protein that allows for the exchange of lipids between lipoproteins, 
ultimately resulting in delivery of cholesterol esters to the liver, where they are 
converted into bile acid [192, 193]. Activation of CETP, therefore, may contribute to 
improved insulin sensitivity with obesity. 
In addition to their role in digestion, bile acids are signaling agents that regulate 
pathways important for glucose metabolism. Treatment of obese humans with the bile 
acid tauroursodeoxycholic acid improves liver and muscle insulin sensitivity [183]. Bile 
acids signal through three pathways to alter metabolism in multiple tissues. The effect of 
bile acids on hepatic insulin sensitivity is in part mediated by Fgf15, which signals 
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through Fgf4r in the liver to promote glycogen storage and reduce gluconeogenesis [14, 
15]. Bile acids are ligands for the nuclear transcription factor Fxr, which induces 
expression of Shp [180, 181]. Fxr and Shp regulate multiple genes involved in liver 
glucose metabolism [182, 194]. Additionally, bile acids signal to muscle through Gpbar1 
to activate type-2 thyroid deiodinase (Dio2), which leads to an increase in muscle 
glucose oxidation by mitochondria [16]. Since bile acids are produced from cholesterol 
in the liver, mechanisms that increase cholesterol delivery to the liver might promote 
insulin sensitivity. 
CETP has been shown to increase RCT in mice [10, 11]. Since mice do not 
naturally express CETP, transgenic mice expressing CETP have been studied [176, 
177]. Because of its lipid transfer capacity, CETP alters lipid uptake and metabolism by 
tissues. CETP has the net effect of increasing delivery of CE to the liver by promoting 
the movement of CE from HDL to VLDL or LDL, which can be taken up by the liver 
through LDLR and VLDLR [10, 192, 193, 195]. CETP also facilitates uptake of CE from 
serum macrophages into HDL, which is then delivered to the liver by scavenger 
receptor B1 (SR-B1)[11, 196]. CE delivered to the liver is converted into bile acids, 
which are stored in the gallbladder and then secreted into the intestine to facilitate 
absorption of lipophilic nutrients. Taken together, these results suggest that increased 
cholesterol delivery to the liver mediated by CETP increases bile acids in the gut and 
their related signaling to promote insulin sensitivity in liver and muscle. To test this 
hypothesis, we assessed insulin sensitivity in HFD fed male and female CETP 
transgenic mice and their non-transgenic littermates. We observed increased gut bile 
acids in female but not male CETP-expressing mice. This increase in bile acid levels 
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corresponded with improved insulin sensitivity and increased bile acid related signaling 
in liver and muscle in CETP-expressing female mice.  Overall, we show that CETP 
expression protects female mice from the metabolic complications of obesity.  
 
Results 
CETP expression does not alter high fat diet-induced weight or adiposity gain in 
males or females  
Age- and weight-matched male and female CETP transgenic mice and their wild-
type littermates (WT) lacking CETP expression were placed on HFD for 4 weeks to test 
their metabolic adaptation to obesity. As expected, CETP activity was significantly 
higher in CETP mice compared to WT in both males and females (Males Fig. 3.1A, 
Females Fig. 3.1E). There was no difference in CETP activity between transgenic males 
and females. Both male and female WT and CETP mice gained similar weight and had 
similar adiposity on HFD (Males Fig. 3.1B, Females Fig. 3.1F Body weight: Table 3.1).  
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Figure 3.1: CETP expression alters serum cholesterol and ileal bile acids in obese 
mice.  A) CETP activity in WT littermates and CETP-transgenic males. B) Adiposity 
before (-) and after (+) HFD in male mice.  C) Serum cholesterol in HFD-fed male mice. 
D) Total fasted ileal bile acids in HFD-fed male mice.  E) CETP activity in WT littermates 
and CETP-transgenic females. F) Adiposity before (-) and after (+) HFD in female mice.  
G) Serum cholesterol in HFD-fed female mice. H) Total fasting ileal bile acids in HFD 
female mice. Data represent mean ± SEM from n = 6-8 animals per group. *p < 0.05.  
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Table 3.1: Additional physiological parameters. Values represent mean ± standard 
deviation. *p < 0.05 versus WT, † p < 0.05 versus pre-HFD, ‡ p <0.05 versus clamp 
baseline. n = 4-8 animals per group 
  
  WT Female CETP Female WT Male CETP Male 
Initial Body Weight (g) 
20.5 ± 2.3 21.0. ± 1.8 24.0 ± 2.1 25.4 ± 3.6 
Post-HFD body weight (g) 26.5 ± 5.1† 24.1 ± 3.6† 28.4 ± 3.2† 32.1 ± 5.0*† 
HFD Fasting Blood Glucose (mg/dL) 152 ± 35.8 134 ± 19.6 148 ± 24.1 151 ± 38.1 
HFD Clamp Insulin (ng/mL) 4.8 ± 1.6 2.6 ± 1.1 2.8 ± 0.6 3.7 ± 1.0 
Chow Clamp Insulin (ng/mL) 1.7 ± 0.4 2.1 ± 0.3 ND ND 
HFD Plasma Free Fatty Acid (mmol/L) 1.44 ± 0.96 1.62 ± 0.50 1.57 ± 0.77 1.44 ± 0.96 
HFD Plasma LDL (mg/dL pooled) 33.8 14.6 39.1 21.7 
HFD Plasma HDL (mg/dL pooled) 110.3 50.0 79.5 52.1 
HFD Basal Glucose EndoRa  (mg·kg-1·min-1) 17.3 ± 7.4 19.6 ± 5.6 10.3 ± 4.4 14.6 ± 10.1 
HFD Clamp Glucose EndoRa (mg·kg-1·min-1) 2.2 ± 2.1‡ 3.9 ± 2.8‡ 3.7 ± 4.8 2.9 ± 5.7‡ 
HFD Clamp Glucose Rd (mg·kg-1·min-1) 17.1 ± 3.4 45.0 ± 6.1* 16.9 ± 4.4 17.19 ± 4.8 
HFD Clamp AUC GIR/Glucose (mg2·min·kg-1·dL-1) 0.10 ±.03 0.25 ± .05* 0.09 ±.03 0.11 ± .02 
HFD Fasting Plasma Triglyceride (mg/dL) 73.8 ± 22.6 53.5± 21.0 46.5 ± 13.0 65.0 ± 15.0 
HFD Clamp Plasma Triglyceride (mg/dl) 51.7 ± 23.1 36.6 ± 5.9 ‡ 43.8 ± 18.6 50.0 ± 11.3 
HFD Liver Cholesterol (mg/g tissue) 2.75 ± 1.5 4.27 ± 2.1 2.47 ± 0.8 3.86 ± 1.6 
HFD Liver Triglyceride (mg/g tissue) 54.8 ± 21.7 75.1 ± 9.4 79.2 ± 20.5 53.8 ± 14.2 
HFD Liver Diacylglycerol (mg/g tissue) 2.67 ± 0.63 2.67 ± 0.61 3.61 ± 1.53 2.53 1.02 
HFD Plasma Interleukin 6 (pg/mL) 77.6 ± 65.7 76.1 ± 31.9 54.3 ± 23.5 113.1 ± 64.2 
HFD Plasma Leptin (ng/mL) 12.9 ± 5.2 10.6 ± 5.8 12.7 ± 0.1 18.6 ± 5.0 
HFD Plasma Adiponectin (µg/mL) 13.1 ± 1.8 15.7 ± 1.8 15.1 ± 1.6 17.6 ± 3.6 
HFD Serum Estradiol (pg/mL) 6.8 ± 3.1 6.9 ± 2.0 ND ND 
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CETP expression reduces serum cholesterol in males and females and increases 
gut bile acid content in females only 
To determine the effect of CETP expression on lipid and bile metabolism, we 
measured fasted serum lipids and ileal bile acids. We observed that CETP expression 
reduced serum cholesterol in both male and female mice (Males Fig. 3.1C, Females Fig. 
3.1G). CETP-expressing males showed no difference in ileal bile acid content compared 
to WT males (Fig. 3.1D). CETP-expressing females, however, showed a significant 
increase in gut bile acid content compared to WT (Fig. 3.1H). We saw a trend towards 
increased bile acid species in the serum of CETP females (Table 3.2). Additionally we 
observed an increased hepatic bile acid species in the CETP females (Table 3.2, 
p<0.05 for genotype effect by 2-way ANOVA). We did not observe a difference in 
plasma free fatty acid, triglyceride, or estradiol (Table 3.1). We saw a trend toward 
increased hepatic cholesterol content in both male and female CETP-expressing mice, 
but this difference was not significant (Table 3.1). Overall, we observed a reduction in 
serum cholesterol in both male and female CETP mice and an increase in gut bile acids 
in female mice only.  
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Figure 3.2: CETP expression decreases fasting plasma insulin in female mice.  A) 
Fasting blood glucose in HFD-fed male mice. B) Fasting plasma insulin in HFD-fed male 
mice. C) Fasting blood glucose in HFD-fed female mice. D) Fasting plasma insulin in 
HFD-fed female mice. All animals were fasted for 5 hours. Data represent mean ± SEM 
from n = 6-8 animals per group. *p < 0.05.  
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Table 3.2: Liver and serum bile acid species. Values represent mean ± standard. † 
indicates significance as a group versus WT by 2-way anova for all marked species. n = 
4 animals per group 
  
  
 WT Male CETP Male WT Female CETP Female 
Liver Bile Acid (nmol/g) 109.5 ± 25.6 81.5 ± 47.6 99.9 ± 20.2 74.9 ± 37.2 
Liver Cholate (AU) ND ND 0.74 ± 0.36 1.27 ± 0.39 † 
Liver Taurocholate (AU) ND ND 0.88 ± 0.27 1.08 ± 0.44 † 
Liver Glycocholate (AU) ND ND 0.84 ± 0.17 1.41 ± 1.10 † 
Liver Taurochenodeoxycholate (AU) ND ND 0.85 ± 0.32 1.15 ± 0.46 † 
Liver Beta-Muricholate (AU) ND ND 1.00 ± 0.04 1.07 ± 0.37 † 
Liver Tauro-Beta-Muricholate (AU) ND ND 1.23 ± 0.36 1.11 ± 0.69 † 
Liver Taurosodeoxycholate (AU) ND ND 1.03 ± 0.14 1.32 ± 0.85 † 
Serum Bile acid (nmol/mL) 10.72 ± 5.80 21.9 ± 25.3 12.6 ± 12.2 37.7 ± 48.6 
Serum Cholate (AU) ND ND 1.26 ± 1.08 2.37 ± 2.49 
Serum 1,2 Dehydrocholate (AU) ND ND 0.68 ± 0.41 1.48 ± 1.41 
Serum Beta-Muricholate (AU) ND ND 1.21 ± 0.87 2.01 ± 1.91 
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CETP expression reduces fasting insulin in female mice 
Since bile acids are known to affect insulin sensitivity, we measured fasting 
glucose and insulin levels in the CETP mice and WT littermates. After 4 weeks of HFD-
feeding, there was no difference in fasting blood glucose between CETP and WT mice 
(Males Fig. 3.2A, Females Fig. 3.2C).  While there was a small but not significant 
reduction in fasting insulin in CETP males compared to WT (Fig. 3.2B), CETP female 
mice had significantly lower fasting insulin levels than WT (Fig. 3.2D). Thus, despite 
weight and adiposity gain on HFD, female CETP mice had lower fasting insulin levels 
than WT, suggesting that they may be protected from HFD-induced insulin resistance. 
 
Expression of CETP protects against diet-induced insulin resistance in female 
mice 
Since the changes in fasting insulin suggested improved insulin sensitivity in the 
CETP female mice, we measured insulin sensitivity using a hyperinsulinemic-
euglycemic clamp in mice fed HFD for 4 weeks (Fig. 3.3A). The hyperinsulinemic-
euglycemic clamp technique assesses insulin sensitivity by determining the glucose 
infusion rate (GIR) required to maintain euglycemia in response to a physiologic 
increase in serum insulin; increased GIR corresponds to greater insulin sensitivity. 
There was modest but non-significant increase in GIR between the CETP and WT 
males during the clamp (Fig. 3.3B-C). Male CETP mice showed no change in insulin 
sensitivity index (SI) compared to WT (Fig 3.3D), which is defined by the GIR divided by 
the average insulin level in the steady-state clamp period.  
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In contrast, CETP females showed a markedly increased GIR compared to WT 
(Fig. 3.3E-F). Additionally, SI was increased by approximately 3-fold in the CETP 
females compared to WT (Fig. 3.3G). Insulin suppressed endogenous glucose 
production (EndoRa) in all groups. The dose of insulin used in the clamp study, however, 
was optimized to study muscle metabolism by maintaining insulin at a concentration 
similar to post-prandial levels (Table 3.1). Glucose rate of disappearance (Rd), an index 
of muscle insulin action, was significantly increased in CETP females compared to WT. 
(Table 3.1). Rd in CETP-expressing females was significantly higher than both WT 
females and CETP-expressing males. Overall, the clamp results show that CETP 
expression significantly improves insulin sensitivity in obese female mice fed HFD.  
To determine if CETP-mediated effects on insulin sensitivity are dependent on 
diet composition, we performed a parallel hyperinsulinemic-euglycemic clamp study on 
CETP and WT females fed a standard chow diet (Fig. 3.3A). We focused on the female 
mice because of the large phenotype observed in the HFD-fed females. In contrast to 
the HFD-fed group, there was no difference in GIR or SI between the chow-fed CETP 
and WT mice, suggesting that the improvement in insulin sensitivity observed with 
CETP expression depends on HFD-feeding (Fig. 3.3H-J). Thus, CETP protects against 
the effect of HFD on insulin sensitivity in females; it has no effect on insulin sensitivity in 
lean chow-fed females. This interaction between CETP and diet in females is consistent 
with a mechanism mediated by bile acid signaling, which would be increased on HFD. 
  
61	  
	  
Figure 3.3: CETP expression protects female mice against diet-induced insulin 
resistance.  A) Hyperinsulinemic-euglycemic clamp study design. B) Clamp blood 
glucose in HFD-fed males. C) Glucose infusion rate (GIR) required to maintain 
euglycemia during hyperinsulinemic clamp in HFD-fed males. D) Insulin sensitivity index 
based on steady-state GIR/insulin for HFD-fed males. E) Clamp blood glucose in HFD-
fed females F) GIR for HFD-fed females. G) Insulin sensitivity index for HFD-fed 
females. H) Blood glucose during clamp in chow-fed females. I) GIR for chow-fed 
females. J) Insulin sensitivity index for chow-fed females. Data represent mean ± SEM 
from n = 6-8 animals per group. *p < 0.05.  
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Figure 3.4: CETP expression alters hepatic insulin signaling and bile acid signal 
related gene expression. A) Immunoblot analysis of Akt, P-Akt (S-473), Erk1/2, P-
Erk1/2, and Actin in liver whole-cell extract from fasted and clamped CETP and WT 
female mice on a HFD. B) Quantification of P-Akt to Akt ratio C) Quantification of P-
Erk1/2 to Erk1/2 ratio D) Gene expression for genes the products of which control 
glucose metabolism, bile acid metabolism, and gene transcription determined by qRT-
PCR from hepatic RNA Data represents the mean ± SEM from n=4 animals per group. 
*p < 0.05 versus fasted, brackets (a) indicate statistical significance for genotype effect 
by 2-way ANOVA. 
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CETP expression increases insulin-stimulated phosphorylation of hepatic Akt 
and Erk1/2 in HFD-fed mice 
To define changes in insulin signaling compared to the fasted state, we added an 
additional non-insulin treated cohort of CETP and WT female mice that were HFD-fed 
for 4 weeks and then fasted for 5 hours with no insulin treatment prior to sacrifice. 
Insulin-stimulated Akt phosphorylation was greater in clamped female CETP mice 
compared to WT (Fig. 3.4A-B). We did see a trend towards increased hepatic AKT 
phosphorylation in the CETP males, although this result was not statistically significant 
(Fig. 3.5).  
We performed western blot analysis for phosphorylation of liver Erk1/2, which 
occurs via multiple pathways including the hepatic estrogen, bile acid, and insulin 
signaling pathways [14, 15, 197]. Erk1/2 phosphorylation was increased in the insulin-
clamped CETP females compared to clamped WT females (Fig. 3.4A, C). Fasting 
Erk1/2 phosphorylation was similar between fasted CETP and WT females, suggesting 
that insulin is required for increased Erk1/2 phosphorylation in CETP female mice (Fig. 
3.4A, C). Erk1/2 phosphorylation was not increased in CETP males (Fig. 3.5). To further 
investigate the sex difference, we performed western blots for estrogen receptor alpha 
(ERα) in liver and muscle of female CETP and WT mice. We did not observe a 
difference in ERα expression between CETP and WT in either liver or muscle (Fig. 3.6). 
Overall, we observed that CETP expression improves the insulin signal to Akt in the 
context of HFD-feeding. Female CETP mice had an additional robust signal to increase 
signaling to Erk1/2, likely contributing to the marked sex-difference seen in our clamp 
study. 
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Figure 3.5: CETP has a modest effect on insulin signaling in male mice on a high 
fat diet. A) Immunoblot analysis of Akt and P-Akt (S-473) from livers of insulin-clamped 
males. B) Quantification of P-Akt to Akt ratio. C) Immunoblot analysis of Erk1/2 and p-
Erk1/2 from liver of insulin clamped males. D) Quantification of P-Erk1/2 to Erk1/2 ratio. 
E) Relative gene expression of G6pc in fasted and clamped males. F) Immunoblot 
analysis of Akt and P-Akt (S-473) from gastrocnemius muscle of insulin-clamped males 
G) Quantification of P-Akt/Akt ratio. Data represent mean ± SEM from n = 6-8 animals 
per group. 
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CETP expression alters expression of genes involved in liver glucose metabolism 
As bile acids were only altered in the female CETP mice, we focused our further 
mechanistic studies of bile acid signaling on female CETP mice versus female WT. To 
determine the effect of CETP expression on hepatic gene expression, we performed 
qRT-PCR on hepatic mRNA from fasted and insulin-clamped CETP and WT female 
mice. We determined mRNA levels for genes the products of which are involved in 
glucose and lipid metabolism and regulate gene transcription (Fig. 3.4D). After HFD-
feeding, insulin failed to suppress glucose-6-phosphatase (G6pc) and phosphoenol 
pyruvate carboxylase (Pck1) expression in the WT mice. These genes products are 
central to control of hepatic gluconeogenesis. Female CETP mice showed improved 
insulin-suppression of mRNA for G6pc and Pck1 compared to WT (Fig. 3.4D). Male 
CETP mice also showed improved insulin suppression of mRNA for G6pc compared to 
WT (Fig. 3.5E) Additionally, insulin-mediated suppression of RNA for sterol CoA 
desaturase expression, a gene the product of which is involved in de-novo lipogenesis, 
was improved in the female CETP mice compared to WT. Female CETP mice had 
increased expression of Hnf4α, Fxr, and Lrh-1, as well as increased Shp under insulin 
treatment. These transcription factors regulate genes the products of which control bile, 
glucose, and lipid metabolism. Based on our observed changes in ileal bile acids, liver 
protein, and mRNA, CETP expression may improve insulin action on control points of 
hepatic glucose metabolism, potentially through bile acid signaling.  
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Figure 3.6: CETP expression does not alter hepatic or muscle levels of ERα. A) 
Immunoblot analysis of ERα in liver of WT and CETP female mice. B) Quantification of 
hepatic ERα protein normalized to actin. C) Immunoblot analysis of ERα in 
gastrocnemius muscle of WT and CETP female mice. D) Quantification of muscle ERα 
protein normalized to actin. Data represent mean ± SEM from n = 4 animals per group. 
 
 
W
T
CE
TP
0.0
0.1
0.2
0.3
0.4
0.5
Li
ve
r E
R
!
/A
ct
in
W
T
CE
TP
0
1
2
3
G
as
tro
c 
ER
!
/a
ct
in
A
B
D
C
CETP!
Actin!
ERα!
+!-!
Female!
CETP! +!-!
Actin!
ERα!
Female!
Gastrocnemius Muscle
Liver
67	  
	  
Figure 3.7: CETP-expressing mice on a high fat diet display improved muscle 
insulin signaling and altered glucose metabolism A) Immunoblot analysis of Akt, P-
Akt (S-473), and Actin in muscle whole-cell extract from fasted and clamped CETP and 
WT female mice. B) Quantification of P-Akt to Akt ratio. C) Metabolite analysis of 
glycolytic and TCA cycle intermediates in muscle of fasted CETP and WT female mice. 
D) Schematic representation of changes in glycolytic and TCA cycle intermediates E) 
Gene expression for Dio2, Cpt1b, and Hk2 determined by qRT-PCR from muscle RNA 
extracts. F) Respiratory quotient determined by indirect calorimetry for HFD fed CETP 
and WT female mice Data represent mean ± SEM from n=4 animals per group except 
for (F) which is n=3 animals per group. *p < 0.05. 
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CETP expression increases insulin-stimulated phosphorylation of muscle Akt in 
HFD-fed mice 
The large increase in GIR and Rd in CETP females was likely due to increases in 
muscle insulin sensitivity, since muscle is the largest depot for insulin-stimulated 
glucose uptake. We measured phosphorylated Akt in gastrocnemius muscle from fasted 
and insulin-clamped CETP and WT females. We observed an increase in Akt 
phosphorylation in response to the insulin in CETP but not WT females (Fig. 3.7 A-B). 
We saw a trend toward increased Akt phosphorylation in muscle of CETP males, but 
this result was not significant (Fig. 3.5 F-G). Western blotting for ERK1/2 
phosphorylation was attempted in muscle tissue from these mice, but the results 
showed significant variability from animal to animal. This result suggests that CETP 
expression ameliorates the HFD-induced decrease in muscle insulin signaling to Akt in 
female mice. 
 
CETP expression reduces muscle glycolytic intermediates 
Having observed improved muscle insulin signaling and increased glucose 
disposal, we measured glycolytic intermediates in muscle tissue from fasted CETP and 
WT females (Fig. 3.7C). CETP animals had significantly decreased levels of glucose-6-
phosphate (G6P) and fructose-6-phosphate (F6P). We also saw a trend towards 
decreased fructose 1,6 bisphosphate (F1,6BP) in the CETP females (p=0.11). 
Glycogen-derived glucose-1-phosphate (G1P) was also significantly decreased. Muscle 
glucose was not altered. Levels of citrate were increased in the CETP mice, an indicator 
of increased glucose and/or lipid oxidation. The reduced glycolytic intermediates despite 
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increased citrate (an inhibitor of glycolysis) suggest that CETP expression promotes 
muscle TCA cycle flux in the fasting state. We examined soleus muscle mRNA for 
genes the products of which promote TCA cycling, and found significantly increased 
gene expression for Dio2, carnitine palmitoyltransferase 1b (Cpt1b), and a trend 
towards increased hexokinase 2 (Hk2) gene expression in CETP mice (Fig. 3.7E: 
p=0.058 for Hk2). Taken together, the reduction in muscle glycolytic intermediates along 
with increased gene expression for Dio2 and Cpt1b suggests that CETP expression 
causes increased muscle substrate oxidation. These changes likely contribute to 
improved insulin sensitivity in CETP females  
 Having observed a significant difference in insulin sensitivity in HFD-fed CETP 
females as well as altered muscle glucose metabolism, we performed indirect 
calorimetry on HFD-fed CETP and WT females to measure energy expenditure. Food 
intake and energy expenditure were similar between CETP and WT, although CETP 
females ate more frequently than WT (Fig. 3.8). Additionally, the increase in respiratory 
quotient showed that CETP females had increased carbohydrate oxidation compared to 
WT (Fig. 3.7F). The finding that CETP expression increases the relative utilization of 
carbohydrate compared to lipid is consistent with our observation that CETP alters 
muscle glucose oxidation. Activation of glycolysis and Dio2 are known effects of bile 
acid signaling in muscle, and these observations are consistent with our model that bile 
signaling is responsible for improved insulin sensitivity in the CETP females 
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Figure 3.8: CETP expression does not alter food intake or energy expenditure in 
HFD-fed female mice. A) Food intake over 12 hour periods. B) Feeding behavior based 
on frequency of feeding events. C) Rate of oxygen consumption. D) Rate of carbon 
dioxide production. E) Heat generation. F) activity level measured by beam breaks. 
Animals were housed in a facility with 12 hour light-dark cycles. The light or dark period 
is indicated below the graph. Data represent the mean ± SEM from n = 3 animals per 
group.  
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Discussion 
Our studies demonstrate a novel role for CETP expression to ameliorate insulin 
resistance in obese female mice. We propose that the increase in bile acids in the 
CETP females improves insulin sensitivity. Our data is consistent with the growing body 
of evidence that bile acids can promote insulin sensitivity [15, 16, 183]. CETP 
expression did not alter bile acid levels in male mice, and, correspondingly, there was 
no alteration in insulin sensitivity in the male CETP mice. Additionally, we did not 
observe a difference in insulin sensitivity between female CETP mice and female WT 
littermates fed chow, suggesting that CETP may have metabolic benefits that promote 
insulin sensitivity only in the context of a lipid-rich diet.  
We propose that the metabolic effect of CETP in female mice is due to 
enhancement of insulin signaling due to the effects of bile acids. We observed induction 
of the bile-sensitive Fxr and Fgf15 signaling pathways in the liver that corresponded 
with alterations of gene expression of Shp, G6pc, and Pck1. We also observed 
increased Erk1/2 phosphorylation in the livers of the CETP female mice, which is a 
known effect of Fgf15 signaling. We also observed effects consistent with activation of 
bile-sensitive pathways in muscle, which likely had a large effect on the phenotype. We 
saw a large increase in the rate of glucose disappearance during our clamp studies, an 
index of muscle glucose disposal. The increase in Rd corresponded with decreased 
glycolytic intermediate metabolites and an increase in the TCA cycle intermediate citrate. 
These effects are consistent with bile acid signaling through Gpbar1 to induce Dio2, 
which was upregulated in the CETP female animals. Impairments in muscle glucose 
disposal are believed to be the first major defect in metabolism that leads to 
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development of diabetes [198]. Therefore, mechanisms that promote muscle glucose 
disposal such as activation of Gpbar1 signaling can protect against development of 
insulin resistance. I propose that the observed increase in muscle glucose disposal in 
the CETP mice is the major mechanism by which they are protected from HFD-induced 
insulin resistance. Collectively, our results show a strong correlation between CETP 
expression in females and increased bile acid signaling in liver and muscle that likely 
results in increased glucose disposal and improved insulin sensitivity. Further study is 
required to determine if bile acid signaling has a truly causative role in this improvement. 
There was no change in insulin sensitivity in the chow-fed CETP-expressing mice 
compared to WT. This result suggests either that HFD feeding is required to induce bile 
acid production or that the chow-fed mice are already insulin sensitive and that CETP 
does not have an additive effect on insulin sensitivity in an already insulin sensitive 
animal. Bile acids are known to be increased by HFD and particularly diets that contain 
high levels of saturated fat such as our 60% lard HFD [199, 200]. We did not measure 
gut bile acids in chow-fed animals and can therefore only speculate that they would 
have lower bile acid levels than the HFD mice. Determining the levels of bile acids in 
these animals will be performed in a future study.  
The role of CETP in human health has been a topic of considerable controversy, 
and there are significant unresolved questions about its effects on lipid and glucose 
homeostasis. CETP promotes the movement of cholesterol esters and triglycerides 
between lipoproteins, resulting in a net flux of cholesterol from HDL to LDL. Since 
reduced HDL is a well-known risk factor for CHD, CETP inhibitor drugs were developed 
with the goal of increasing HDL and reducing CHD. While the inhibitors successfully 
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raised HDL in humans, the clinical benefit of these drugs on CHD has not yet been 
established  [9, 153]. These findings, along with our data, suggest that CETP may have 
important additional effects on metabolism. 
Studies in humans have also suggested that CETP may have sex-specific roles 
in glucose metabolism [13, 163, 201]. We observed a pronounced sexual dimorphism in 
insulin sensitivity between the male and female CETP mice, which is consistent with 
differences observed between men and women in human studies. In our studies, CETP 
expression did not significantly improve insulin sensitivity in males. Although the GIR 
was higher in CETP males in our clamp study, mice in the CETP group also had higher 
blood glucose levels in the clamp period. Two measures of insulin sensitivity, SI and the 
AUC of the GIR/glucose, were not different in male CETP vs. WT.  
Reciprocally, studies in females suggest beneficial effects of CETP on 
cholesterol efflux and glucose metabolism. Higher CETP activity is associated with 
increased transfer of CE from macrophages to HDL in women but not men [12, 131]. 
This improved cholesterol transport capacity with increased CETP was independent of 
HDL cholesterol [12]. In women, CETP polymorphisms that increase CETP activity 
correlated with reduced risk of ischemic heart disease [162]. Higher CETP activity is 
associated with improved glucose metabolism after roux-en-Y gastric bypass in women 
but not men [13, 163]. In our studies, we found that female CETP mice had 3-fold 
improvement in insulin sensitivity with HFD-feeding compared to WT, showing a strong 
protection of female CETP mice against diet-induced insulin resistance.  
The observed sexual dimorphism in insulin sensitivity in our study may be due to 
sex-differences in bile acid signaling. CETP female mice showed a significant increase 
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in ileal bile acids compared to WT; CETP males showed no difference in ileal bile acid 
levels compared to WT littermates. These observations show that CETP expression 
increases ileal bile acid content in a sex-specific manner. This difference in bile content 
correlates with the observed increases in bile acid related signaling in the CETP-
expressing females. Additionally, estrogen may augment the bile signal in female CETP 
mice, as both CETP and estrogen signaling through ERα increase bile secretion [202, 
203]. We observed alterations in signaling pathways that were unique to the females, 
such as increased hepatic Erk phosphorylation and increased Shp gene expression, 
pathways that are shared between estrogen and bile-signaling pathways [14]. CETP 
has also been shown to augment estradiol delivery to tissues, enhancing estrogen 
signaling [204, 205]. We did not, however, observe an increase in ERα levels in liver or 
muscle of CETP-expressing mice, and CETP-expressing females had levels of 
circulating estradiol similar to WT. Since bile acids were increased in females but not 
males, I propose that the mechanism for the observed sex difference in insulin 
sensitivity lies in the alteration in gut bile acids observed in the CETP-expressing 
females. The ability of gut bile acids to signal to Dio2 in muscle through Gbpar1 leads to 
increased muscle glucose disposal, which is a known factor to promote whole-body 
insulin sensitivity [198].   
We observed a trend towards improved insulin sensitivity in the male CETP mice. 
Hepatic G6pc gene expression was suppressed by insulin in the CETP-expressing male 
mice fed HFD, suggesting improved hepatic insulin sensitivity. This result is consistent 
with our tracer data that show suppression of hepatic glucose production during the 
clamp. We also observed a trend towards increased AKT phosphorylation in both liver 
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and muscle in the CETP expressing males. While these results are not significant, the 
studies may have been underpowered to detect the moderate changes caused by 
CETP expression in the males. For example, based on the mean and standard 
deviation for liver Akt phosphorylation, 9 animals would be required to achieve 80% 
power whereas the study group contained only 6 animals per group. The changes 
observed in the CETP expressing males are not likely caused by an effect of CETP on 
bile acids, as there was no difference in gut bile acids between CETP and WT males. 
While the size of the gut bile acid pool did not change in the CETP-expressing males, it 
is possible that the bile acid species composition was altered by CETP expression. 
Changes in bile acid species independent of pool size have been shown to improve 
insulin sensitivity [18]. The trend towards improved insulin sensitivity in the CETP males 
may also relate to the intracellular function of CETP to promote storage of lipids in 
adipose tissue, which is a topic for future investigation.  
Our finding that CETP expression promotes insulin sensitivity does not 
necessarily suggest that CETP inhibition would be harmful with regard to glucose 
homeostasis. CETP has an extracellular role in lipid transfer between lipoproteins but 
also functions intracellularly to promote CE uptake and direct partitioning of CE between 
subcellular compartments [206, 207]. If our effects were mediated by intracellular CETP, 
we would not expect CETP inhibition to adversely impact the phenotype [206]. 
Additionally, several CETP inhibitors promote RCT, culminating in increased CE 
delivery to the liver and bile secretion [157, 208]. The mechanism for this improvement 
of RCT appears to be improved lipidation of nascent HDL [157]. In contrast, CETP’s role 
to promote RCT is dependent on flux of CE from HDL to LDL, which is then cleared by 
76	  
	  
LDLR in the liver [10, 11]. Mechanisms that promote RCT would be predicted to 
increase bile acid signaling and perhaps improve insulin sensitivity.  
In humans, dietary weight-loss strategies are complicated by weight regain. 
Pharmacologic strategies to achieve weight loss often have significant side effects on 
the cardiovascular system or central nervous system. Strategies to improve insulin 
sensitivity in the setting of obesity would be an attractive alternative to weight loss. The 
idea of “metabolically healthy obesity” is an important goal in the prevention of diabetes 
and cardiovascular risk associated with obesity. We observe a metabolically-healthy 
obese phenotype in female CETP mice. The model shown here, though dissimilar to the 
human in some regards, demonstrates an important proof-of-principle that augmenting 
aspects of CETP function, such as bile acid signaling, may be a therapeutic approach to 
improve insulin sensitivity and lessen the negative metabolic impact of obesity.  
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CHAPTER IV 
 
CETP EXPRESSION PROTECTS FEMALE MICE FROM OBESITY-INDUCED 
DECLINE IN EXERCISE CAPACITY 
 
Introduction 
Obesity carries with it a significant increase in risk of diabetes and heart disease 
[22, 23]. Adherence to an exercise program can help obese patients to lose weight and 
reduce the risk of complications of obesity. In a study of patients who had lost weight, 
89% reported using a combination of diet and increased physical activity to achieve 
weight loss, whereas only 10% achieved weight loss by diet alone [2]. Unfortunately, 
obesity leads to reduced exercise tolerance, making weight loss through exercise more 
difficult [4]. Beyond its role in weight loss, exercise capacity is critical to overall health, 
as impaired exercise capacity correlates with increased risk of death from all causes 
[184].  Additionally, impaired exercise capacity was identified as a stronger predictor 
than BMI of mortality among men with diabetes [185].  Therefore, it is important to 
identify novel factors that might help improve exercise tolerance in obese individuals. 
A crucial factor for exercise capacity is the ability of the body to properly deliver 
oxygen to muscle and its ability to effectively perform oxidative metabolism. Exercise 
capacity is often measured by VO2max, which is defined as the maximal rate that oxygen 
can be taken up and utilized during exercise [188]. Several factors play into oxygen 
utilization including the ability of lungs to extract oxygen, the ability of the heart to pump 
oxygen through the blood, the oxygen carrying capacity of the blood, and muscle and 
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mitochondrial function. Pulmonary function can become a limiting factor for VO2max in 
highly trained athletes and is not usually a limiting factor for healthy untrained 
individuals [186]. Cardiac output is very important to VO2max, and exercise training leads 
to an increase in maximal cardiac output that leads to improvement in VO2max [187].  
The ability of skeletal muscle to oxidize fuel substrates is crucial to exercise 
capacity. A study of patients with congestive heart failure showed that changes in 
muscle metabolism correlated with decreased exercise capacity [209]. Additionally, 
reduced muscle oxidation has been observed in impaired glucose tolerance and 
diabetes and may be linked to the age-related decline in exercise capacity [210]. 
Endurance training leads to increased TCA cycle flux in the mitochondria [189]. We 
have previously shown that female mice expressing CETP are protected against the 
effect of HFD on insulin sensitivity [211]. This improvement in insulin sensitivity was 
marked by increases in muscle glycolysis. At higher levels of exercise intensity, muscle 
is increasingly dependent on glycolysis as fuel, as opposed to lower intensity exercise, 
which is primarily dependent on fatty acid oxidation [212]. Because the CETP-
expressing mice showed increased muscle glycolysis, we propose that CETP-
expressing female mice might have improved oxidative capacity and increased exercise 
tolerance when fed HFD. 
Increased HDL or ApoA1 has recently been demonstrated to improve exercise 
capacity. Specifically, mice overexpressing ApoA1 showed improved exercise capacity 
and were resistant to age-related decline in exercise capacity [213]. These results 
suggest that either RCT mediated by HDL or the HDL particle itself acts to improve 
exercise capacity. We were interested in defining exercise capacity in the CETP 
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transgenic mouse, a mouse model that has improved RCT and a lipid profile more 
similar to a human than a wild-type mouse. CETP is a lipid transfer protein that 
facilitates the movement of cholesteryl esters and triglycerides between lipoproteins. 
CETP activity results in a net flux of CE from HDL into the ApoB containing lipoproteins 
LDL and VLDL, which are then delivered to the liver via LDL receptor in a process 
termed reverse cholesterol transport. This flux allows for an SR-B1 independent method 
for CE to be cleared by the liver. CETP expression increases RCT in SR-B1 knockout 
mice but not LDL receptor knockout mice [11]. HDL cholesterol is reduced in the CETP 
mice, but the lipid flux between lipoproteins is more humanlike. CETP-expressing mice 
therefore provide a model of increased RCT with more humanlike levels of HDL.  
To test the hypothesis that CETP activity can improve exercise capacity, we 
measured exercise capacity in CETP-expressing female mice. While there was no 
difference in exercise capacity on chow diet, HFD-fed CETP-expressing mice were 
protected from the obesity-related decline in exercise capacity. This improvement in 
exercise capacity corresponded with an increase in mitochondrial oxidation.  
 
Results 
CETP expression does not alter exercise tolerance in chow-fed female mice 
To test the effect of CETP expression on exercise tolerance in female mice, we 
performed an exercise study in CETP-expressing female mice and their non-transgenic 
female littermates. At the beginning of the study, mice were 12 weeks old, had been fed 
a standard chow diet, and were lean. Groups were matched by initial body weight and 
body composition (Fig. 4.1 A-B). Mice were subjected to an exercise tolerance test 
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consisting of a treadmill run with speed increasing every 3 minutes. The duration and 
distance run by the mice provide an index of exercise capacity. In the initial exercise 
tolerance test, we saw no difference in exercise capacity between lean, chow-fed CETP 
mice and their WT littermates. CETP mice ran for an average of 22.9±2.3 minutes 
(535.3 ± 89.5 meters) versus 24.0±1.9 minutes (586 ±169.8 meters) for the WT mice 
(Fig 4.1 C-D). These results show that there is no genotype effect of CETP expression 
on exercise capacity in the context of a low-fat chow diet. 
 
CETP expression protects female mice from high fat diet-induced decline in 
exercise capacity 
Because obesity induces a decline in exercise capacity, we measured the 
changes in exercise capacity in CETP-expressing female mice and their non-transgenic 
littermates over a period of HFD feeding. Following the initial exercise test, mice were 
switched from a normal chow diet to a 60% HFD to induce obesity. Exercise capacity 
was measured every 2 weeks for 6 weeks using the same exercise tolerance test 
protocol used in the initial measurement. HFD feeding effectively induced weight gain 
and increased adiposity in the mice. By 4 weeks on HFD, both groups had gained over 
15% of their initial weight and showed a significant increase in fat mass (Fig 4.1 A-B). 
This increase in weight and adiposity corresponded with a decrease in exercise 
capacity in both groups. The CETP-expressing mice, however, had a smaller reduction 
in exercise capacity compared to WT. The CETP mice decreased from 22.9±2.3 
minutes (535.3 ± 89.5 meters) to 14.8 ± 3.6 minutes (271.5 ± 99.4 meters), while the 
WT mice decreased from 24.0±1.9 minutes (586 ±169.8 meters) to 10.4 ± 1.8 minutes 
81	  
	  
(157.6 ± 38.7 meters) (Fig. 4.1 C-E). While the CETP-expressing mice showed a 49% 
decrease in run distance over 6 weeks of HFD, the WT mice showed a much larger 
73% decrease in run distance over the same 6 weeks of HFD feeding. These results 
indicate that the CETP-expressing mice are protected from the deleterious effect of 
obesity on exercise capacity.   
 
 
CETP-expressing mice show increased muscle oxidative capacity 
To define muscle function after a matched exercise period, mice were kept on 
HFD for a total of 12 weeks, after which they were subjected to a single 15-minute bout 
of exercise at a constant speed of 16 m/min. Immediately following exercise, mice were 
sacrificed and tissues were collected. Muscle fibers from the red gastrocnemius muscle 
were isolated immediately following sacrifice, and mitochondrial oxidative capacity in 
these muscles was determined ex-vivo using an oxygraph-2k system. The muscle fibers 
were treated with either glutamate-malate or palmitoylcarnitine to measure the response 
to TCA cycle intermediates or ATP production from fatty acid oxidation. We observed a 
significant increase in oxygen consumption in the CETP-derived muscle fibers when 
treated with the glutamate/malate mixture but not the palmitoylcarnitine mixture (Fig 4.2). 
This result indicates that the CETP-expressing mice have higher oxidative capacity in 
muscle mitochondria but have a similar level of fatty acid oxidation. This is consistent 
with our prior observations that CETP-expressing female mice show increased 
glycolysis and TCA cycle intermediates. These results suggest that the mechanism for 
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the observed improvement in exercise capacity is an increased ability of muscle to 
oxidize carbohydrate in the CETP-expressing mice. 
 
Figure 4.1: CETP expression protects female mice against HFD-induced decline in 
exercise capacity. A) Body weight over the course of HFD feeding. B) Body 
composition at baseline and 4-weeks post HFD. C) Run duration in each exercise test. 
D) Total distance run per mouse in the initial exercise test. E) Total distance run per 
mouse in the 6-week post HFD exercise study. Error bars represent mean ± SEM. n= 5-
8 mice per group. 
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Figure 4.2: CETP expression increases mitochondrial oxidation in female mice. A) 
Oxygen consumption in isolated muscle fibers treated with glutamate/malate mixture to 
measure total substrate oxidation. B)  Oxygen consumption in isolated muscle fibers 
treated with palmitoylcarnitine to measure fatty acid oxidation. Data represent mean ± 
SEM. n = 8-14 muscle fibers per group. 
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Discussion 
 A decline in exercise capacity with obesity creates a vicious cycle of worsened 
insulin resistance and further impairment in exercise capacity. I aimed to determine if 
CETP expression has an effect on exercise capacity in female mice. Overall, I observed 
that CETP-expressing female mice are relatively protected against HFD-induced 
exercise intolerance compared to WT. The improvement in exercise capacity on HFD 
corresponds with increased mitochondrial oxidative capacity in the CETP female mice 
compared to WT littermates. These results are consistent with our previous observation 
that CETP-expressing female mice have increased muscle glucose flux to the TCA 
cycle and a preferential oxidation of carbohydrate compared to fatty acid. These results 
suggest that mechanisms that improve RCT may help to improve mitochondrial function 
and exercise capacity in people with obesity.  
We used CETP-expressing mice to test the hypothesis that increasing RCT 
independently of HDL would lead to improved exercise capacity. Recent studies have 
linked HDL levels and ApoA1 to improved exercise capacity, although the mechanism 
by which HDL improves exercise capacity has not been fully explored [213]. Our results 
suggest that high levels of HDL are not required for improved exercise capacity, but 
rather that increasing RCT leads to improved exercise capacity in the context of high-fat 
feeding. Overexpression of ApoA1 corresponded with improved exercise capacity and 
increased mitochondrial oxidation [213].  We also observe an increase in mitochondrial 
oxidative capacity in the CETP-expressing female mice compared to WT mice fed HFD. 
Decline in mitochondrial oxidative capacity has been observed with obesity and aging, 
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and is likely responsible for the impairments in exercise capacity observed in these 
conditions [214, 215].  
A potential link between the lipid transfer activity of CETP and the observed 
improvement in mitochondrial oxidation is bile acid signaling to muscle through Gpbar1. 
CETP expression increases RCT and efflux of cholesterol to feces in the form of bile 
acids [11]. GPBAR1 signaling has been shown to increase energy expenditure in brown 
fat and skeletal muscle [16, 17]. We have observed increased gut bile acids in the 
CETP-expressing mice and increased transcription of Dio2, which is a target of 
GPBAR1 signaling [211]. Additionally, the fact that the CETP and WT mice did not show 
a difference in exercise capacity on the chow diet suggests that increased bile acids 
may be necessary for an effect on exercise capacity. Bile acids are known to be 
increased by high-fat diets, particularly those that contain high amounts of saturated fat 
[199, 200]. When placed on HFD, the CETP female mice display increased gut bile 
acids (Fig 3.1H). The changes in RCT that are mediated by CETP may therefore 
account for the improvement in exercise capacity observed in the CETP-expressing 
female mice. Alternatively, the lack of a difference in exercise capacity between chow-
fed CETP and WT mice may indicate that there is not an additive effect of CETP activity 
on exercise capacity in metabolically healthy animals but rather that CETP protects 
against the deleterious effect of obesity on exercise capacity.  
 Improving exercise capacity in the context of obesity represents an attractive 
target for treating obesity. Impaired exercise capacity has been correlated with 
increased risk of death from all causes, and obesity causes a reduction in exercise 
capacity. We identify a novel role for CETP to protect female mice against the obesity-
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related decline in exercise capacity. This improvement in exercise capacity correlated 
with improved muscle glucose oxidation, which is indicative of bile acid signaling to 
muscle. Mechanisms that promote RCT may therefore promote healthy muscle function 
in the context of obesity.   
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CHAPTER V 
 
SUMMARY AND CONCLUSIONS 
 
Promoting metabolic heath in the context of obesity 
 Obesity has become a serious health issue throughout the world, being declared 
a global epidemic by the WHO. Obesity has a deleterious effect on human health by 
increasing risk of CHD and type-2 diabetes. The deleterious effects of obesity can 
sometimes be prevented by weight loss; however, maintaining weight loss is difficult, 
and recent studies have suggested that weight loss may not be enough to reverse the 
effects of obesity. In the Look AHEAD trial, obese people with type-2 diabetes were 
treated with an intensive lifestyle intervention based on reduced caloric intake and 
increased physical activity or a control treatment of diabetes education and support. The 
lifestyle intervention was successful, resulting in weight loss (8.6% of body weight), 
reduced waist circumference, reduced hemoglobin a1c, improved exercise capacity, 
and improvement in markers for cardiovascular risk such as reduced blood pressure 
and increased HDL cholesterol [216]. Surprisingly, despite the improvement in multiple 
risk factors for CHD, there was no difference in the incidence of cardiovascular events 
between the lifestyle intervention group and the control group [216]. These results 
suggest that weight loss may not be enough to reverse the effects of obesity on CHD in 
the context of type-2 diabetes.  Therefore, mechanisms that can improve metabolic 
health in the context of obesity are attractive targets to study with the goal of treating the 
deleterious effects of obesity. 
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A novel role for CETP expression to promote healthy obesity in mice 
 I have shown that CETP is a previously unrecognized factor that can promote 
healthy obesity. My studies have demonstrated that CETP-expressing female mice are 
protected against the deleterious effects of obesity on insulin sensitivity and exercise 
capacity. I propose that CETP’s ability to promote RCT leads to an increase in bile acid 
signaling that ultimately results in improved muscle glucose disposal that improves 
systemic insulin sensitivity (Fig 5.1). I have observed increased activation of bile acid 
signaling pathways and physiological effects are reflective of bile acid signaling. These 
effects correspond with improved insulin sensitivity and increased insulin signaling in 
liver and muscle. While CETP was previously thought to have a negative effect on risk 
of CHD, my studies suggest that it promotes metabolic health in the context of obesity, 
particularly in females. The observed sexual dimorphism is also supported by studies of 
CETP in humans.  Additionally, with the future of CETP inhibitor drugs in question, my 
research has provided additional insight into the role of CETP and may help contribute 
to a better understanding of the appropriate usage of CETP inhibitor drugs. On the 
whole, my research has demonstrated a novel role for CETP in protecting against the 
negative metabolic effects of obesity. 
 
Clinical Relevance: CETP expression increases bile acid signaling 
 Once thought to function mainly in digestion, recent studies have demonstrated 
that bile acids have significant signaling roles. I have demonstrated that CETP 
expression leads to a significant increase in bile acids in the gut. This increase in bile 
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acids corresponds with increased Dio2 transcription in gastrocnemius muscle, which is 
known to be upregulated by the activity of the bile acid receptor Gpbar1. This 
corresponds with improved muscle glucose disposal, resulting in improved insulin 
sensitivity. I also observed increased bile acid associated signaling in the liver through 
the Fxr and Fgf15/19 pathways, although these effects were only seen in the presence 
of insulin.  
 I propose that bile acid signaling, particularly the activation of Gpbar1 in muscle, 
is the mechanism by which CETP protects against diet-induced insulin resistance. 
Gpbar1 activity is known to increase energy expenditure and glucose oxidation in brown 
adipose tissue and muscle. I observed increased muscle glycolysis, TCA cycling, and 
glucose disposal in the CETP-expressing female mice, which is consistent with the 
effect of Gpbar1 signaling on muscle. A Gpbar1 agonist, INT777, is currently in 
development. Study of INT777 in mice has shown that activating Gpbar1 improves 
insulin sensitivity in mice fed HFD [16] and also reduces atherosclerotic lesions in a 
mouse model of atherosclerosis [217]. These results suggest that specifically targeting 
Gpbar1 signaling can lead to improved metabolic health. 
 Bile acids have shown promise in humans as a treatment for obesity-induced 
insulin resistance. A 4-week oral course of treatment with the bile acid 
tauroursodeoxycholic acid (TUDCA) in obese humans caused an increase in hepatic 
and muscle insulin sensitivity as determined by hyperinsulinemic clamp [183]. 
Additionally, muscle Akt phosphorylation was increased by treatment with the bile acid. 
Since the gut is easily accessible by oral treatment, these results suggest that bile acids 
could be a possible drug to treat the metabolic complications of obesity. The study of 
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TUDCA treatment showed an improvement in insulin sensitivity comparable to 
treatment with traditional anti-diabetes drugs such as thiazolinediones and metformin 
[218, 219]. Bile acid treatment could potentially provide an alternative anti-diabetic 
treatment, especially given the concerns regarding possible linkages between 
thiazolinediones and elevated risk of heart disease [220]. 
 The composition of bile acids in the gut and serum may be more important than 
the total amount of bile acids. A study of the bile acid sequestrant colesevelam 
demonstrated that colesevelam treatment reduces the bile acid pool size but has the 
same effect on improving glucose tolerance, insulin sensitivity, and energy expenditure 
as treatment with bile acids [18]. Both the bile acid-treated mice and the colesevelam-
treated mice were resistant to the effects of HFD on insulin sensitivity. While the bile 
acid-treated mice had 2.6-fold more bile acids in the gut and nearly twice in the serum, 
the treatments appeared to have the same effect on metabolism. Interestingly, both the 
bile acid-treated mice and the colesevelam-treated group showed a significant increase 
in the proportion of the bile acid pool consisting of taurocholic acid, which is known to be 
a strong agonist for Gpbar1 [221], so increasing the amount of a specific bile acid that 
activates Gpbar1 may be sufficient to promote insulin sensitivity.  
 Overall, my dissertation project has shown an important role for bile acid 
signaling in promoting insulin sensitivity in obese mice. Bile acids and their related 
signaling pathways are a strong drug target as the gut is easily accessible through oral 
delivery. Bile acids are also naturally occurring in the gut, which should likely reduce the 
possibility of side effects. I predict that bile acid signaling will become a pathway of 
great interest clinically as a method of promoting metabolic health in obesity.  
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Clinical Relevance: Sexual dimorphism in the effect of CETP on metabolism 
 I observed a significant sexual dimorphism in insulin sensitivity in the CETP-
expressing female mice. While there was a modest improvement in GIR and some 
evidence for improved insulin sensitivity in the male mice, the female CETP-expressing 
mice showed a large difference in insulin sensitivity. Therefore, I focused the exercise 
studies on female mice only. The mechanism by which this sexual dimorphism occurs is 
yet to be determined. Evidence from human and mouse studies, however, suggest that 
CETP has a beneficial role in RCT and glucose metabolism in females. CETP may have 
a significant effect on estrogen signaling due to its role in production and trafficking of 
esterified estrogens. Additionally, female sex hormones may interact with CETP to 
promote RCT and increase bile acid production through their effect on hepatic LDL 
receptor. Overall, I propose that the sexual dimorphism is most likely caused by 
increased RCT in CETP female mice that leads to increased bile acid production, 
increased muscle glucose disposal, and therefore improved insulin sensitivity. 
The sexual dimorphism that I observed with regard to CETP is supported by 
recent findings from studies in humans. CETP has a stronger effect on RCT in women, 
as studies of ex-vivo RCT showed that serum from women with higher CETP activity 
was better able to promote efflux of cholesterol from macrophages to serum. 
Additionally, clinical studies of surgical weight loss by gastric bypass surgery have 
shown that CETP mass correlated with reduced glycemia at a 12-month follow-up [13]. 
These results, combined with the strong sexual dimorphism observed in my studies 
suggest an interaction between CETP and female sex hormones that promotes RCT 
and improves metabolic health in the context of obesity. Interestingly, I did not observe 
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a difference in circulating estrogen levels or estrogen signaling to ERα in either liver or 
muscle, suggesting that absolute levels of estrogen or signaling through ERα do not 
account for the observed phenotype.  
CETP expression may increase the amount of esterified estrogen in the serum, 
which may have an effect on estrogen signaling. Because of their hydrophobicity, 
estrogen esters must be carried through the circulation in lipoproteins. Estrogens can be 
esterified by LCAT in HDL and then transferred into LDL though the activity of CETP 
[222]. Esterified estrogen has been demonstrated to prevent LDL oxidation. Since 
oxidized LDL can contribute to formation of atherogenic plaques, estrogen esters likely 
have an anti-atherogenic role. Additionally, estrogen esters, which reside in serum 
lipoproteins, may be able to target estrogen signaling to specific tissues. I propose that 
CETP may not only increase the levels of esterified estrogen in LDL but also increase 
delivery of estrogen esters to the liver. In the liver, estrogen is known to have important 
signaling roles in promoting insulin sensitivity. Hepatic knockout of ERα, one of the main 
targets of estrogen signaling, results in hepatic insulin resistance [36]. Therefore, CETP 
may have insulin sensitizing effect in females through its effect on estrogen ester 
formation and trafficking.    
Alternatively, CETP may not change estrogen signaling, but estrogen may 
instead have an effect on hepatic cholesterol uptake that promotes CETP-mediated 
RCT. The ability of CETP to promote RCT is dependent on hepatic LDL receptor [11]. 
Interestingly, estrogen is one of the most potent activators of LDL receptor expression in 
the liver [223, 224]. In fact, treatment of men with estrogen also increases hepatic LDL 
receptor expression and increases the rate of LDL clearance from the serum [225]. 
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Additionally, our lab has observed that LDLR protein level is reduced in the livers of 
obese mice that lack ovarian hormones in a model of surgical menopause [226]. Since 
bile acid signaling appears to be central to the insulin sensitivity and exercise tolerance 
phenotypes observed in the CETP female mice, the increase in LDL receptor by 
estrogen may allow for CETP to promote RCT and increase bile secretion. The increase 
in bile acids leads to increased activation of Dio2 in muscle through the action of 
Gpbar1, resulting in increased muscle glucose oxidation. This hypothesis is supported 
by my observation that only female CETP mice showed increased gut bile acids. 
Therefore, induction of hepatic LDL receptor by estrogen signaling is likely central to 
both the sexual dimorphism and the overall protection of female CETP mice from the 
metabolic effects of HFD. 
CETP likely has a positive effect on RCT and glucose metabolism in women. My 
results from CETP-expressing female mice further contribute evidence to this 
hypothesis. The mechanism by which female sex interacts with CETP has not been fully 
established, but I propose that estrogen regulation of LDL receptor is central to the 
observed phenotype. CETP’s ability to promote RCT depends on LDLR. Therefore, 
increased LDLR expression by estrogen could help CETP promote RCT and increase 
gut bile acids. Additional study of this mechanism could contribute to a better 
understanding of lipoprotein metabolism in women.  
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Figure 5.1: Overall model for the effect of CETP activity on bile acid signaling and 
hepatic and muscle insulin sensitivity. I propose that CETP mediates increased 
delivery of CE to the liver through LDLR. Once in the liver, CE is converted to bile and 
secreted into the gut. Gut bile acids can: 1) recycle to the liver and activate the Fxr 
signaling pathway, resulting in reduced gluconeogenesis, 2) Activate FGF15/19 
production which signals to Fgf4r in the liver to promote glycogen production and 
suppress gluconeogenesis, or 3) Escape the enter-hepatic circulation into the systemic 
circulation, where they can activate Gpbar1 to promote glucose oxidation and energy 
expenditure in brown adipose tissue and muscle. This increase in glucose disposal 
leads to an improvement in insulin sensitivity in both liver and muscle tissue.  
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Clinical Relevance: Future of CETP inhibition 
 CETP inhibitor drugs have been controversial in the medical and pharmaceutical 
community because their failure to protect against CHD goes against well-established 
models of cardiovascular risk. Inhibition of CETP leads to a significant increase in HDL 
levels, which, according to the current model of cardiovascular risk, should lead to a 
significant reduction in incidence of cardiovascular events. Surprisingly, clinical trials of 
CETP inhibitor drugs have not demonstrated clinical efficacy in terms of reducing death 
from cardiovascular events. The CETP inhibitor Torcetrapib was associated with a 
higher incidence of death from cardiovascular causes, while the CETP inhibitor 
Dalcetrapib did not show a significant effect on reducing incidence of cardiovascular 
events. Clinical trials of Anacetrabpib, a third CETP inhibitor drug, are currently ongoing. 
While the CETP inhibitor class of drugs has not yet demonstrated clinical efficacy in 
reducing risk of CHD, there may still be some hope for these drugs in promoting RCT. 
 My dissertation work on CETP suggests that improving RCT through the action 
of CETP overexpression improves insulin sensitivity. Interestingly, there is seemingly 
paradoxical evidence that inhibition of CETP leads to improved RCT. Treatment of 
model organisms with Torcetrapib [227], Dalcetrapib [157], and Anacetrapib [208] 
corresponds with improved RCT. If increased RCT promotes insulin sensitivity in the 
context of obesity, inhibition of CETP should cause improved insulin sensitivity. In a 
post-hoc study of the clinical trials of Torcetrapib, a correlation between CETP inhibition 
by Torcetrapib and a modest improvement in insulin sensitivity was observed [201]. This 
study, however, was performed mainly in men (approximately 70% of the study 
population), and the women in the study were post-menopausal, so effects of female 
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sex were likely not observed in this study. Studying CETP inhibition in younger women 
could help provide a further understanding of the intersection between CETP inhibition 
and female sex.  
The ability of CETP inhibitor drugs to promote RCT depends on HDL-mediated 
flux of cholesterol to the liver, as CETP inhibition increases HDL cholesterol and 
reduces LDL cholesterol.  CETP inhibitors are proposed to improve RCT by promoting 
lipidation of nascent HDL [157]. In contrast, CETP promotes RCT by increasing LDL 
cholesterol and its clearance by LDL receptor[10, 11]. The pathway by which HDL and 
LDL promote RCT may be central to the phenotype that I observed in the CETP-
expressing female mice. Since LDLR is upregulated by the activity of estrogen signaling 
[223, 224], women may have a larger capacity for RCT by LDL. Also, a number of 
studies in humans have suggested a correlation between CETP activity and RCT in 
women [12, 131]. Considering these outcomes, it appears that CETP inhibition might 
have a deleterious effect on RCT in women. 
Overall, these results suggest that improving RCT by CETP inhibition could 
improve insulin sensitivity by increasing HDL-mediated delivery of cholesterol to the 
liver. CETP promotes RCT through LDL. The significance of cholesterol delivery to the 
liver by LDLR versus SR-B1 has not been fully investigated. Since CETP inhibitor drugs 
increase RCT but do not have a large effect on insulin sensitivity, I speculate that RCT 
by LDLR may have a more significant effect than RCT mediated by HDL/SR-B1 on bile 
acid production and insulin sensitivity. 
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Conclusions 
 Obesity is an increasingly prevalent health problem that increases the risk of 
developing diabetes and CHD. While weight loss can reverse the negative effects of 
obesity, long-term weight loss maintenance is difficult. Additionally, weight loss may not 
reverse the effects of obesity on CHD in people with type-2 diabetes. Therefore, 
methods to improve metabolic health in obesity must be identified. My dissertation 
project has identified CETP as a factor that protects females against the negative 
effects of obesity on insulin sensitivity and exercise capacity. I propose that this 
protection is mediated by the signaling effects of bile acids, which are increased in only 
female mice. These results both provide insight into the relative protection of women 
from CHD and suggest that targeting bile acid signaling is a potential therapeutic 
method for protecting against insulin resistance and exercise intolerance in obesity. 
These findings could help to lessen the burden of obesity on both individuals and 
healthcare systems by spurring the development of treatments that promote 
metabolically healthy obesity.  
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CHAPTER VI 
 
FUTURE DIRECTIONS 
 
Insulin sensitivity in CETP mice 
Bile acid signaling 
 My dissertation work has demonstrated that CETP protects against obesity 
induced insulin resistance in female mice. I propose that the ability of CETP to promote 
RCT leads to an increase in gut bile acids, which have been associated with improved 
insulin sensitivity in liver and muscle and increased energy expenditure in muscle and 
brown adipose tissue. Bile aids signal through three major pathways: 1) Fxr in the liver, 
2) Fgf15 signaling to FGFR4 in liver, and 3) Gpbar1 in muscle. I propose the following 
future directions that will further investigate the relative contributions of each pathway to 
the observed phenotype of improved insulin sensitivity.  The long-term goal of this work 
has been to define pathways that can convert obesity from an unhealthy state to a 
metabolically healthy state. These aims will define the relative contribution of three 
different bile acid signaling pathways to the metabolically healthy obesity phenotype 
observed in the CETP-expressing mice. 
 
1: Evaluate insulin sensitivity in HFD-fed CETP-expressing mice treated with a Shp 
siRNA. 
 Bile acid signaling and estrogen signaling in the liver converge on the induction 
of Shp, a transcriptional co-repressor that downregulates genes the products of which 
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control gluconeogenesis. Shp is induced by both bile acid signaling through Fxr and 
estrogen signaling through ERα. Knocking down Shp with an anti-sense oligo (ASO) will 
allow for the assessment of the role of hepatic Fxr and ERα signaling to Shp in the 
observed improvement in insulin sensitivity mediated by transgenic expression of CETP 
in female mice. I propose assessing insulin sensitivity in HFD-fed CETP-expressing 
female mice treated with the Shp ASO or scrambled ASO. I expect that the knockdown 
of Shp will result in increased transcription of G6pc and Pck1 in the liver, as Shp is 
known to repress their transcription. I do not expect the Shp knockdown to have a 
significant effect on muscle, as the ASO will be localized to the liver. I expect that 
knockdown of Shp will not alter the insulin sensitivity phenotype observed in CETP 
expressing mice, as I predict that the phenotype of improved muscle glucose disposal 
will still promote insulin sensitivity in the context of Shp knockdown. The insulin signal to 
the liver will likely still be strong enough to suppress G6pc and Pck1 gene expression 
even in the context of Shp knockdown.   Determining the relative contribution that 
hepatic bile and estrogen signaling to Shp makes towards the insulin sensitivity 
phenotype will help provide a better understanding of the mechanism by which CETP 
expression improves insulin sensitivity in HFD-fed female mice.  
 
2: Evaluate insulin sensitivity in HFD-fed CETP-expressing mice crossed with a Fgf4r 
knockout mouse. 
 Bile acids in the gut promote the production of the enterokine Fgf15/19, which 
signals to the liver through Fgf4r. Fgf4r signaling leads to decreased bile acid 
production and suppression of genes the products of which control gluconeogenesis. 
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Knocking out Fgf4r will allow us to assess the role of Fgf15/19 signaling to the liver in 
promoting insulin sensitivity in the CETP-expressing female mice. I propose to evaluate 
insulin sensitivity in the in CETP-expressing female mice that have Fgf4r knocked out or 
control CETP-expressing female mice fed HFD. I expect that the knockout of Fgf4r will 
result in decreased ERK1/2 phosphorylation in the liver and a reversal of the effects of 
CETP on G6pc and Pck1 signaling. I expect that the Fgf4r knockout mice will show 
reduced hepatic glycogen storage capacity and increased hepatic gluconeogenesis, as 
FGF15/19 signaling through Fgf4r is known to promote glycogen storage and suppress 
gluconeogenesis in the liver. I expect that the Fgf4r knockouts, therefore, will result in a 
relative reduction in the insulin sensitivity phenotype observed in the CETP-expressing 
females. I also expect that cyp7a1 will be increased in the Fgf4r knockout mice, as 
Fgf4r signaling downregulates cyp7a1. This effect may prove confounding, as increased 
cyp7a1 promotes bile acid signaling and may increase the effect of bile acid signaling 
on muscle [228]. This study will allow us to determine if Fgf4r signaling to the liver is 
required for the observed changes in insulin sensitivity in the CETP-expressing mice.  
 
3: Evaluate insulin sensitivity in HFD-fed CETP transgenic mice that are deficient in 
Gpbar1. 
 A portion of bile acids (approximately 5%) escape the entero-hepatic circulation 
and enter into the serum. These bile acids activate a third bile acid receptor known as g-
protein coupled bile acid receptor (Gpbar1). Gpbar1 signaling increases glucose 
oxidation in brown fat and skeletal muscle and may have an important role in the 
improved insulin sensitivity in the CETP-expressing female mice. Gpbar1 also acts in 
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the gut to promote secretion of Glp1, which is known to promote insulin secretion and 
has a protective effect on pancreatic beta cells. Crossing the CETP transgenic mouse 
line into a mouse model that lacks Gpbar1 expression will define if bile acid signaling 
through Gpbar1 is necessary for the resistance to diet-induced insulin resistance 
observed in the CETP-expressing female mice. I propose to evaluate insulin sensitivity 
in the in CETP/Gpbar1ko mice or control CETP-expressing female mice fed HFD. 
 I expect that knocking out Gpbar1 will reverse the protective effects of CETP 
expression on insulin sensitivity in the context of HFD. In my previous studies, I 
observed changes in the muscle of the CETP-expressing mice that are consistent with 
Gpbar1 signaling such as increased glycolysis, increased TCA cycle intermediates, and 
increased expression of Dio2, which is a known target of Gpbar1. I therefore expect that 
the CETP/GPBAR1ko mice would not show increased glycolysis or increased muscle 
glucose disposal and would therefore have impaired whole-body insulin sensitivity 
compared to the CETP-expressing mice. This experiment is critical to understanding the 
involvement of bile acid signaling in the CETP-expressing mice, as our previous 
observations suggest that Gpbar1 signaling is central to the observed improvement in 
insulin sensitivity. If Gpbar1 knockout does not alter whole-body insulin sensitivity, I 
propose that effects of bile acids on hepatic signaling to Shp and Fgf4r might be the 
main link between bile acids and the observed improvement in insulin sensitivity in 
CETP female mice. Additionally, bile acids promote secretion of Glp1 in the gut, which 
has an insulin sensitizing effect. Overall, this study will determine the contribution of bile 
acid signaling to muscle through Gpbar1.  
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4: Quantify the levels of bile acid species in the CETP-expressing female mice 
Recent studies of the role of bile acid signaling in metabolism have suggested 
that the composition of bile acid species may be more important than the size of the bile 
acid pool itself. In fact, bile acid sequestrants that decrease the bile acid pool size had a 
similar effect on insulin sensitivity to bile acid treatment [18]. Increased levels of 
taurocholic acid, which is a strong ligand for Gpbar1, were correlated with improved 
insulin sensitivity. Different bile acid species have variable degrees of potency in 
activating bile acid signaling pathways. For example, chenodeoxycholic acid is the 
strongest natural agonist for Fxr [229], while lithocholic acid is the strongest Gpbar1 
agonist [230]. In my studies I measured bile acid species in liver, gut, and serum using a 
metabolomic approach that was optimized for more hydrophilic biochemicals. By 
performing a more targeted measurement of bile acid species, we can determine the 
effect of CETP expression on bile acid species, which could potentially contribute to the 
improvement in insulin sensitivity observed in the CETP-expressing female mice by 
differential activation of different bile acid signaling pathways. 
 
Sexual dimorphism 
I observed a significant sexual dimorphism in insulin sensitivity in the CETP-
expressing mice, with CETP expression having a much greater effect on insulin 
sensitivity in the female mice compared to the males. I propose that this sexual 
dimorphism is related signaling by female sex hormones, particularly estrogen. 
Estrogen signaling interacts with multiple signaling pathways critical to insulin 
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sensitivity, especially AKT and ERK signaling in the liver. Additionally, estrogen 
signaling is known to increase expression of LDLR in the liver, which is likely critical to 
CETP’s ability to promote RCT. Investigating the role of estrogen signaling in CETP-
expressing mice will allow for greater understanding of the observed sexual dimorphism 
in insulin sensitivity. I propose the following aims to investigate the mechanism of the 
sexual dimorphism in insulin sensitivity observed in the CETP-expressing mice. 
Understanding mechanisms that contribute to sex differences in the effect of CETP 
could help to provide further insight into the sexual dimorphism observed in CETP 
function in humans. CETP appears to have a beneficial role to promote RCT and 
improve glycemic control in women [12, 13, 131]. Additionally, since women are 
relatively protected from the risk of CHD, CETP expression could potentially be 
contributing to the reduced relative risk in human women. Further understanding of the 
interaction between female sex and CETP could help provide insight into the role of 
CETP in CHD in women. 
 
1: Assess insulin sensitivity in CETP mice that lack ovarian hormones 
Since we observed a strong phenotype with regards to insulin sensitivity in the 
female CETP mice only, I propose that female sex hormone signaling contributed to the 
observed phenotype. To test the hypothesis that female sex hormones are required for 
insulin sensitivity in the CETP-expressing female mice, ovarian hormones will be 
eliminated by surgical removal of the ovaries by ovariectomy. Ovariectomy will globally 
remove the contribution of all ovarian hormones to metabolism. I propose measuring 
insulin sensitivity in HFD-fed CETP females and WT littermates that have been either 
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treated with ovariectomy or sham surgery. If the ovariectomized CETP mice have 
similar insulin sensitivity to the WT sham mice, it would suggest that ovarian hormones 
are required for the protection against HFD-induced insulin resistance observed in the 
CETP female mice. I expect that the ovariectomized CETP female mice will not be 
protected against HFD-induced insulin sensitivity, as this effect appeared to depend on 
the presence of female sex hormones. Additionally, I expect that the ovariectomized 
mice will show lower levels of hepatic LDLR, which will interfere with CETP’s ability to 
promote RCT. This study will improve our understanding of the mechanism by which 
female sex influences insulin sensitivity in CETP mice.  
 
2: Assess insulin sensitivity in CETP-expressing mice that lack hepatic ERα expression 
 Estrogen signaling to ERα in the liver is known to promote insulin sensitivity, as 
mice lacking ERα exhibit insulin resistance. To test the hypothesis that hepatic estrogen 
signaling is required to improve insulin sensitivity in CETP-expressing female mice, 
CETP mice will be bred with mice that lack ERα in the liver (Liver ERα knockout or 
LERKO). ERα signaling is known to alter hepatic metabolism, and liver ERα knockout 
mice exhibit hepatic insulin resistance. I propose measuring insulin sensitivity in female 
CETP mice and CETP/LERKO mice fed a HFD as well as WT littermate controls. If the 
CETP/LERKO mice show impaired insulin sensitivity compared to the CETP females, it 
would then appear that hepatic estrogen signaling is required to protect against HFD-
induced insulin resistance in CETP mice. I expect that hepatic knockout of ERα in the 
CETP mice will reverse the phenotype of improved insulin resistance observed in the 
female CETP-expressing mice. Since ERα promotes expression of LDLR in the liver, I 
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expect that ERα knockout will interfere with CETP’s ability to promote RCT, which I 
hypothesize is the mechanism by which CETP improves insulin sensitivity. This study 
will allow us to understand the specific contribution of hepatic ERα signaling to the 
insulin sensitivity phenotype in CETP female mice.  
  
3: Assess insulin sensitivity in male CETP mice that have been treated with estrogen 
 Since the insulin sensitivity phenotype mediated by transgenic expression of 
CETP is only observed in females, I hypothesize that female sex hormones such as 
estrogen are responsible for the difference in insulin sensitivity. To test the hypothesis 
that elevated estrogen signaling is sufficient to protect CETP mice against HFD-induced 
insulin resistance, I propose treating male CETP mice and their WT littermates with 
estrogen. Males normally have low levels of estrogen signaling, and increasing estrogen 
in males by implanting an estrogen pellet will increase estrogen signaling throughout the 
body. There is evidence from estrogen-treated human males that pharmacological 
doses of estrogen in males increases hepatic LDL receptor and accelerates the 
clearance of LDL [225]. I propose measuring insulin sensitivity in male HFD-fed CETP 
mice and their WT littermates treated with either an estrogen pellet or sham surgery. If 
the estrogen-treated CETP-expressing males show improved insulin sensitivity on HFD 
compared to the control CETP mice and estrogen-treated WT mice, it would suggest 
that estrogen signaling interacts with CETP activity to protect against HFD-induced 
insulin resistance. I expect to see an increase in hepatic LDL receptor in the estrogen 
treated mice. Since the RCT activity of CETP is dependent on LDL receptor levels, I 
expect that the estrogen-treated CETP males would show improved insulin sensitivity 
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compared to the control CETP males. This result would suggest that estrogen signaling 
is sufficient to improve insulin sensitivity in HFD-fed CETP-expressing mice and would 
provide further insight into the observed sexual dimorphism in insulin sensitivity.  
 
CETP mouse model 
I used a mouse model of CETP that constitutively expresses CETP. Human 
CETP expression is regulated by diet, insulin, and ovarian hormones. Therefore, the 
improvement in insulin sensitivity and exercise capacity observed in the CETP 
transgenic mice may be a result of constitutive CETP expression. A second mouse 
model is available that expresses CETP under control of the human promoter. Studying 
HFD-induced insulin resistance in a mouse model that expresses CETP under the 
control of the human CETP promoter would allow us to further investigate the role of 
CETP in insulin sensitivity. Human CETP expression is increased by obesity [165] and 
estrogen [166], and its activity is acutely suppressed by insulin [167].  I propose 
assessing insulin sensitivity in male and female human CETP transgenic mice and their 
non-transgenic littermates fed 4 weeks of HFD. If the mice that express human CETP 
do not show an improvement in insulin resistance on HFD compared to littermates, it 
suggests that acute insulin suppression of CETP activity may impair the ability of CETP 
to improve insulin sensitivity. I expect that the female HFD-fed human CETP-expressing 
mice will show resistance to diet-induced insulin resistance, as obesity and estrogen 
increase CETP levels. The sexual dimorphism may be more pronounced in the human 
CETP mice, as CETP expression will likely be lower in males. This study will allow for 
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further testing of our hypothesis that CETP protects against HFD-induced insulin 
resistance to a more human-like model. 
 
Exercise capacity in CETP mice 
Bile acid signaling 
 I observed that CETP prevents the decline in exercise capacity associated with 
obesity in female mice. This improvement in exercise capacity correlated with increased 
muscle glycolysis and TCA cycling. Additionally, mitochondrial oxidative capacity was 
increased in the CETP-expressing mice compared to WT littermates. These results 
suggest an increase in muscle Gpbar1 signaling, which has been associated with 
increased energy expenditure and mitochondrial oxidation.  Additionally, increased 
expression of Dio2, a target of bile acid signaling through Gpbar1 was observed in the 
muscle of CETP-expressing female mice. I propose that bile acid signaling through 
Gpbar1 in muscle leads to the improvement in exercise capacity observed in the female 
CETP mice. I propose the following aims to test the hypothesis that muscle Gpbar1 
signaling improves exercise capacity by promoting mitochondrial glucose oxidation. 
  
1: Determine if Gpbar1 signaling is necessary for improved exercise capacity in CETP-
expressing mice 
 Bile acid signaling to Gpbar1 increases glucose oxidation in brown adipose 
tissue and skeletal muscle. I observed changes in glycolysis, TCA cycling, and 
mitochondrial function in the CETP-expressing female mice that were consistent with 
Gpbar1 signaling. I hypothesize that CETP promotes bile acid production leading to 
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increased activation of Gpbar1, which allows for improved exercise capacity.  To test 
the hypothesis that bile acid signaling through Gpbar1 is the mechanism by which 
CETP expression improves exercise capacity in HFD fed mice, I propose performing 
exercise capacity tests in female HFD-fed CETP mice and CETP/GPBAR1ko mice. If 
the CETP/GPBAR1ko mice show reduced exercise capacity compared to the CETP 
mice, it would seem that bile acid signaling through Gpbar1 is required for the 
improvement in exercise capacity observed in the CETP female mice. Since I observed 
a number of effects that are consistent with Gpbar1 signaling in the muscle of CETP 
female mice, I expect that knocking out Gpbar1 will decrease the exercise capacity 
phenotype observed in the CETP female mice. This study will allow us to determine 
whether bile acid signaling to Gpbar1 leads to CETP improves exercise capacity and 
will help define pathways that may improve exercise capacity in obese people. 
 
2: Determine if Gpbar1 activity is sufficient to improve exercise capacity 
 Signaling through Gpbar1 leads to increased glucose oxidation in brown adipose 
tissue and skeletal muscle. Since exercise capacity depends on the ability of muscle to 
oxidize substrate, I hypothesize that increasing Gpbar1 signaling would lead to 
improved exercise capacity. To test this hypothesis, I propose assessing exercise 
capacity in male and female HFD-fed WT mice treated with the Gpbar1 agonist INT777 
or vehicle. If the INT777 mice show improved exercise capacity compared to the 
vehicle-treated mice it would suggest that activation of Gpbar1 is sufficient to improve 
exercise capacity in the context of HFD. Investigating the specific role of Gpbar1 in 
exercise capacity will allow for a better understanding of the role of bile acid signaling in 
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the CETP-expressing female mice and will determine if Gpbar1 activation alone is 
sufficient to improve exercise capacity.  
 
Sexual dimorphism 
 Based on the strong sexual dimorphism observed in insulin sensitivity in the 
CETP mice, I focused the exercise studies on female mice only, as they showed 
significantly improved insulin resistance compared to the CETP male mice. It is 
possible, however, that CETP-expressing male mice might have a difference in exercise 
capacity despite not showing a large change in overall insulin sensitivity when fed HFD. 
Therefore, I propose that exercise capacity should be studied in CETP-expressing male 
mice. Male CETP-expressing mice and their WT littermates would be subjected to an 
exercise test every 2 weeks while being fed HFD. If the CETP-expressing male mice 
show improved exercise capacity during the course of HFD compared to the WT 
littermates, it would suggest that there is not a significant sexual dimorphism in CETP-
expressing mice with regard to exercise capacity. Since we did not observe an 
improvement in insulin sensitivity or an increase in gut bile acids in the CETP-
expressing male mice, I do not expect to observe an improvement in exercise capacity 
in the HFD-fed CETP-expressing male mice compared to WT. If the CETP-expressing 
males do show improved exercise capacity on HFD, it would suggest that the 
mechanism by which CETP improves exercise capacity is separate from the 
mechanism that leads to improved insulin sensitivity. 
 
 
110	  
	  
Human studies 
 My studies have shown that CETP expression improves exercise capacity in 
female mice. We are interested in expanding on the results from mice by investigating 
the role of CETP in exercise capacity in human females. To test the hypothesis that 
CETP activity improves exercise capacity in female humans, we have established a 
collaboration with Dr. Peter Bovary at the University of Michigan, who has studied 
female endurance athletes. We are planning to measure CETP activity in blood samples 
from trained athletes and untrained, age and BMI matched controls. If we observe a 
higher level of CETP activity in the highly trained athletes compared to controls it would 
suggest that CETP has a role in improving exercise capacity in humans. This study, 
however, would only establish a correlation between CETP and exercise capacity in 
female endurance athletes. Additionally, since both the athletes and controls are lean, 
this study would not investigate the effects of CETP on protecting against the obesity-
induced decline in exercise capacity. In the ideal human study, CETP mass and/or 
activity would be correlated against exercise capacity in obese human females. If CETP 
expression has the same effect on improving exercise capacity in humans, I would 
expect that the patients with higher CETP mass/activity would show improved exercise 
capacity. These experiments will allow for a better understanding of the role of CETP in 
human exercise capacity and could potentially establish CETP as a diagnostic marker 
for exercise capacity. 
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Conclusions 
 My dissertation project has demonstrated a novel role for CETP to protect female 
mice against HFD-induced insulin resistance and exercise intolerance. I have identified 
multiple pathways that may promote metabolically healthy obesity and have provided 
insight into the mechanism of sex differences in the role of CETP. My findings have 
raised questions for ongoing study regarding the contributions of bile acid signaling 
through Fxr, Fgf15/19, and Gpbar1 to improved metabolic health with obesity. 
Determining which of these pathways has the strongest effect on improved metabolic 
health could help provide new drug targets with the goal of improving insulin sensitivity 
and exercise capacity in obese people. Additionally, further investigation into the 
mechanism behind the strong sexual dimorphism observed in the CETP-expressing 
mice could lead to an improved understanding of the sexual dimorphism observed in 
clinical studies of CETP function as well as potentially address the sex difference 
observed in CHD in women. Overall, my studies represent a significant contribution to 
the understanding of the role of CETP in metabolic health and have raised important 
questions for ongoing studies that could lead to better treatments for the chronic 
metabolic effects of obesity. 
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